👪

Inheritance

1

Autosomal Recessive HP:0000007

Autosomal recessive. Heterozygotes are clinically unaffected but not biologically silent: they have increased HIF-1-alpha activity and appear to be protected from anemia, with the odds of anemia reduced about 5.6-fold compared with non-carriers. That heterozygote advantage is the leading explanation for why an allele that shortens homozygote life expectancy has persisted at 5.7% in Chuvashia and 7.0% on Ischia. The allele descends largely from a single ancient founder event, but not exclusively so, since at least one Turkish homozygote carries a distinct haplotype.

Autosomal recessive inheritance

Show evidence (2 references)

PMID:21606165 SUPPORT Human Clinical

"By multivariate logistic regression, the odds of anemia were reduced an estimated 5.6-fold in the VHL(R200W) heterozygotes compared to controls (95% confidence interval 1.4-22.7; P=0.017)."

Quantifies the proposed heterozygote advantage that would maintain the allele in the population.

PMID:14726398 SUPPORT Human Clinical

"Although endemic to the Chuvash population of Russia, this mutation occurs worldwide and originates from a single ancient event."

Establishes the founder origin of the allele and its worldwide occurrence.

◈

Mechanistic Hypotheses

2

Impaired pVHL-HIF Degradation with Normoxic HIF Stabilization

canonical_hif_stabilization CANONICAL

Evidence balance 1 support

The established account. R200W weakens pVHL binding to hydroxylated HIF-alpha, HIF-1-alpha and HIF-2-alpha escape proteasomal degradation at normal oxygen tension, and the hypoxia-response transcriptional program runs constitutively, producing erythropoietin excess, pulmonary vascular changes, altered iron handling, and metabolic reprogramming. Mouse epistasis assigns the erythroid and pulmonary arms specifically to HIF-2-alpha.

Pathograph links

Impaired pVHL Binding to Hydroxylated HIF-alpha -> Normoxic HIF-alpha Stabilization DIRECT Reduced pVHL binding slows HIF-alpha degradation, so HIF-alpha accumulates despite normal oxygen tension.

Normoxic HIF-alpha Stabilization -> HIF Target Gene Program Activation DIRECT Stabilized HIF-alpha dimers drive transcription of the hypoxia-response program despite normoxia.

Normoxic HIF-alpha Stabilization -> Pulmonary Vascular Tone and Remodeling DIRECT HIF-2-alpha activity drives the pulmonary vascular phenotype, which mouse genetics show develops independently of the polycythemia.

HIF Target Gene Program Activation -> Erythropoietin Excess and Erythroid Expansion DIRECT Transcriptional induction of EPO raises circulating erythropoietin about tenfold for the prevailing hemoglobin.

HIF Target Gene Program Activation -> Prothrombotic State DIRECT HIF-driven signaling, indexed clinically by the erythropoietin elevation, is what tracks thrombotic risk. This edge runs in parallel with the erythroid arm rather than through it.

Show evidence (1 reference)

PMID:12415268 SUPPORT Human Clinical

"The protein VHL modulates the ubiquitination and subsequent destruction of hypoxia-inducible factor 1, subunit alpha (HIF1alpha)."

States the normal pVHL function whose impairment is the basis of this model.

Loss of VHL-SOCS1-Mediated Degradation of Phospho-JAK2

vhl_socs1_jak2_dysregulation ALTERNATIVE

Evidence balance 2 support 1 refute

A competing account of why erythroid progenitors are hypersensitive to erythropoietin. pVHL is proposed to heterodimerize with SOCS1 to form an E3 ligase that degrades phosphorylated JAK2, and Chuvash-associated VHL mutants are proposed to have altered SOCS1 affinity and to fail to degrade phospho-JAK2, so erythropoietin signaling runs hot independently of HIF. A selective JAK2 inhibitor reversed the phenotype in the knock-in mouse. Human data cut against it: the Croatian H191D genotype, which the model treats the same way, has erythroid progenitors that are explicitly not hypersensitive to erythropoietin. Recorded as an alternative rather than dismissed, because the mouse rescue is real and the isolated human report of clinical improvement on a JAK2 inhibitor is consistent with it, though JAK2 inhibition would blunt erythropoietin signaling regardless of why that signaling is high.

Show evidence (3 references)

PMID:21685897 SUPPORT Model Organism

"Here we show that VHL directly binds suppressor of cytokine signaling 1 (SOCS1) to form a heterodimeric E3 ligase that targets phosphorylated JAK2 (pJAK2) for ubiquitin-mediated destruction."

States the proposed alternative E3 ligase mechanism.

PMID:21685897 SUPPORT Model Organism

"Systemic administration of a highly selective JAK2 inhibitor, TG101209, reversed the disease phenotype in Vhl(R200W/R200W) knock-in mice, an experimental model that recapitulates human Chuvash polycythemia."

The mouse rescue that is the strongest support for this alternative model.

PMID:23403324 REFUTE Human Clinical

"This observation contrasts with a report suggesting that polycythemia in VHL R200W and H191D homozygotes is due to the loss of JAK2 regulation from VHL R200W and H191D binding to SOCS1."

Human progenitor data contradicting the model's prediction for H191D, which is why it is curated as ALTERNATIVE rather than canonical.

?

Discussions and Knowledge Gaps

4

Why does a homozygous germline VHL mutation not cause the tumors that define von Hippel-Lindau syndrome?

OPEN QUESTION chuvash_absent_tumor_phenotype

Attached to

pathophysiology#Impaired pVHL Binding to Hydroxylated HIF-alpha

This is an absence with a mechanism, and worth curating as one. Three explanations converge. First, dose: R200W is a hypomorph retaining substantial pVHL function, whereas classical VHL tumors require much deeper biallelic inactivation. Second, sufficiency: the matched cohort found no hemangioblastomas, renal carcinomas, or pheochromocytomas despite raised HIF-1-alpha and vascular endothelial growth factor, so HIF overexpression is not sufficient for tumorigenesis. Third, a preserved HIF-independent function: pVHL stabilizes hydroxylated TFAM to sustain mitochondrial biogenesis, tumorigenic VHL variants fail to bind hydroxylated TFAM, and the R200W protein still binds it. That last result is a clean molecular dissociation between the erythrocytosis arm and the oncogenic arm.

Show evidence (2 references)

PMID:14726398 SUPPORT Human Clinical

"Spinocerebellar hemangioblastomas, renal carcinomas, and pheochromocytomas typical of classical VHL syndrome were not found, suggesting that overexpression of HIF-1alpha and VEGF is not sufficient for tumorigenesis."

The sufficiency argument, stated by the authors from matched-cohort data.

PMID:35760869 SUPPORT In Vitro

"In contrast, cells harbouring the Chuvash polycythaemia VHLR200W mutation, involved in hypoxia-sensing disorders without tumour development, are capable of binding hydroxylated TFAM."

The preserved-function argument: R200W retains the HIF-independent TFAM interaction that tumorigenic variants lose.

Does HIF-2-alpha inhibition reduce thrombosis and mortality in VHL R200W homozygotes, or does it only normalize the hematocrit, which is not what kills people?

KNOWLEDGE GAP chuvash_hif2a_inhibition_outcome_endpoint

Attached to

pathophysiology#Prothrombotic State

Belzutifan reverses polycythemia and pulmonary hypertension in the mouse, and a human case of response exists in a compound heterozygote. But the disease's own literature has established that hematocrit is not the determinant of thrombotic risk, so a therapy validated on hematocrit is being validated on the wrong endpoint. The trial that matters would have to be powered on thrombotic events, in R200W homozygotes, with erythropoietin rather than hematocrit as the intermediate marker. Belzutifan also carries a known anemia and hypoxia toxicity profile, and HIF-2-alpha inhibition overshoots easily.

Proposed experiments

HIF-2-alpha inhibition with a thrombotic-event endpoint

chuvash_hif2a_thrombosis_endpoint_trial

A controlled trial of HIF-2-alpha inhibition in VHL R200W homozygotes powered on incident thrombotic events rather than hematocrit, with serum erythropoietin as the mechanistic intermediate and haemoglobin monitored for the known overshoot into anemia.

Show evidence (1 reference)

PMID:37435906 SUPPORT Human Clinical

"Erythropoietin elevation, but not hematocrit or ferritin, correlated with thrombosis risk."

Establishes why a hematocrit endpoint would not answer the question that matters.

Should iron be repleted in Chuvash erythrocytosis, given that iron deficiency raises pulmonary artery pressure but iron repletion has never been studied in a patient with suppressed hepcidin and HIF-driven iron avidity?

KNOWLEDGE GAP chuvash_iron_repletion_question

Attached to

pathophysiology#Hepcidin Suppression and Iron Mobilization

Low ferritin independently predicts higher tricuspid regurgitation velocity, and the commonest cause of low ferritin in these patients is the phlebotomy their doctors prescribe. The obvious corrective, iron repletion, has not been tested in a physiology where hepcidin is suppressed threefold and transferrin and transferrin receptor are transcriptionally induced. There is also a signal that iron status determines which HIF isoform dominates, so repletion could shift the phenotype in a direction that is not simply the reverse of the depletion.

Show evidence (1 reference)

PMID:21993671 SUPPORT Human Clinical

"Lower ferritin concentration, which is associated with phlebotomy, independently predicts higher tricuspid regurgitation velocity (www.clinicaltrials.gov identifier NCT00495638)."

Establishes the harm of the iron-depleted state and its iatrogenic origin, which is what makes repletion an urgent open question.

Does any current management of Chuvash erythrocytosis change outcome?

KNOWLEDGE GAP chuvash_no_controlled_trials

Attached to

treatments#Therapeutic Phlebotomy

There are no randomized trials in this disease. Everything in the treatments section is cohort inference, expert opinion, mouse data, or single cases. The two most-used interventions, phlebotomy and aspirin, have both failed to show benefit in retrospective analysis, and phlebotomy is additionally associated with harm on two separate axes. The authors of the definitive cohort work called for prospective study two decades ago and it has not happened.

Show evidence (1 reference)

PMID:16673284 SUPPORT Human Clinical

"Retrospective analyses among patients with Chuvash polycythemia have not shown benefit for therapy with phlebotomy or aspirin, but these and other modes of therapy should be studied prospectively."

States both the absence of demonstrated benefit and the outstanding call for prospective evaluation.

⚙

Pathophysiology

9

Impaired pVHL Binding to Hydroxylated HIF-alpha

pVHL is the substrate-recognition subunit of a Cullin-2 RING E3 ubiquitin ligase. Under normal oxygen tension, prolyl hydroxylases hydroxylate conserved prolines in HIF-1-alpha and HIF-2-alpha, pVHL binds the hydroxyproline, and the HIF-alpha subunit is polyubiquitinated and destroyed by the proteasome. The Arg200Trp substitution weakens that interaction. It does not abolish it, and that distinction carries the whole disease: a hypomorph produces a chronically mis-set oxygen thermostat, where a null would produce the tumor syndrome.

Impaired pVHL-HIF Degradation with Normoxic HIF Stabilization

VHL hgnc:12687

proteasome-mediated degradation of HIF-alpha GO:0043161 ↓ DECREASED HIF-alpha ubiquitination GO:0016567 ↓ DECREASED

Downstream

Normoxic HIF-alpha Stabilization Reduced pVHL binding slows HIF-alpha degradation, so HIF-alpha accumulates despite normal oxygen tension.

Show evidence (2 references)

PMID:12415268 SUPPORT Human Clinical

"Our data indicate that the Arg200Trp substitution impairs the interaction of VHL with HIF1alpha, reducing the rate of degradation of HIF1alpha and resulting in increased expression of downstream target genes including EPO (encoding erythropoietin), SLC2A1 (also known as GLUT1, encoding solute..."

The discovery paper establishing that R200W impairs pVHL-HIF binding and slows HIF-alpha degradation.

PMID:37435906 SUPPORT Human Clinical

"This mutation impairs binding of VHL to HIF-α subunits and therefore decreases ubiquitin-mediated degradation."

Restates the molecular lesion as impaired binding with consequent reduced ubiquitin-mediated degradation.

Normoxic HIF-alpha Stabilization

HIF-1-alpha and HIF-2-alpha accumulate and dimerize with HIF-1-beta at normal oxygen tension. The cell believes it is short of oxygen while sitting in ordinary room air, which is why the whole phenotype reads as permanent altitude acclimatization. Both isoforms are elevated in patients, but they are not interchangeable: mouse genetics show heterozygosity for Hif2a, and not Hif1a, suppresses both the polycythemia and the pulmonary hypertension, so HIF-2-alpha is the dominant effector for the erythroid and pulmonary-vascular arms.

Impaired pVHL-HIF Degradation with Normoxic HIF Stabilization

normoxic hypoxia response GO:0001666 ⇑ GAIN OF FUNCTION

Animal models

VhlR200W knock-in mouse Mouse perturbs Genetic reduction of Hif2a, but not Hif1a, in this background suppresses both the polycythemia and the pulmonary hypertension, which is the experiment that assigns isoform responsibility.

Downstream

HIF Target Gene Program Activation Stabilized HIF-alpha dimers drive transcription of the hypoxia-response program despite normoxia.

Pulmonary Vascular Tone and Remodeling HIF-2-alpha activity drives the pulmonary vascular phenotype, which mouse genetics show develops independently of the polycythemia.

Show evidence (2 references)

PMID:21876117 SUPPORT Human Clinical

"VHL(R200W) homozygotes have elevated hypoxia-inducible factor 1α (HIF-1α) and HIF-2α levels, increased red cell mass, propensity to thrombosis, and early mortality."

Confirms that both HIF-alpha isoforms are elevated in patients, not just HIF-1-alpha as the original discovery paper framed it.

PMID:20197624 SUPPORT Model Organism

"HIF-2alpha activity was increased in lungs from VhlR/R mice, and heterozygosity for Hif2a, but not Hif1a, genetically suppressed both the polycythemia and pulmonary hypertension in the VhlR/R mice."

Genetic epistasis in the knock-in mouse establishing HIF-2-alpha rather than HIF-1-alpha as the dominant effector isoform.

HIF Target Gene Program Activation

The stabilized HIF dimers transcribe the full hypoxia-response program at normal oxygen: erythropoietin, the glucose transporter SLC2A1, transferrin and its receptor, vascular endothelial growth factor, and endothelin-1. This is the fan-out point of the disease, and it is why a single amino-acid change produces phenotypes in blood, lung, vasculature, iron handling, and muscle metabolism at once. Note that hypoxic regulation itself remains intact and correctly shaped; only the setpoint has moved.

Impaired pVHL-HIF Degradation with Normoxic HIF Stabilization

cellular response to hypoxia GO:0071456 ↑ INCREASED

Downstream

Erythropoietin Excess and Erythroid Expansion Transcriptional induction of EPO raises circulating erythropoietin about tenfold for the prevailing hemoglobin.

Prothrombotic State HIF-driven signaling, indexed clinically by the erythropoietin elevation, is what tracks thrombotic risk. This edge runs in parallel with the erythroid arm rather than through it.

Hepcidin Suppression and Iron Mobilization Transferrin and transferrin receptor induction together with hepcidin suppression reconfigure systemic iron handling.

Metabolic Reprogramming Toward Glycolysis Induction of glycolytic enzymes and pyruvate dehydrogenase kinase shifts substrate use toward glycolysis.

Increased Solid Organ Size HIF-2-alpha-driven proliferation with reduced p21 enlarges liver, spleen, and kidney relative to body mass.

Show evidence (2 references)

PMID:12415268 SUPPORT Human Clinical

"Our data indicate that the Arg200Trp substitution impairs the interaction of VHL with HIF1alpha, reducing the rate of degradation of HIF1alpha and resulting in increased expression of downstream target genes including EPO (encoding erythropoietin), SLC2A1 (also known as GLUT1, encoding solute..."

Enumerates the induced target genes that constitute this node.

PMID:14726398 SUPPORT Human Clinical

"Thus, Chuvash polycythemia is a distinct VHL syndrome manifested by thrombosis, vascular abnormalities, and intact hypoxic regulation despite increased basal expression of hypoxia-regulated genes."

Establishes that basal hypoxia-gene expression is raised while hypoxic regulation itself remains intact, which is the defining shape of this node.

Erythropoietin Excess and Erythroid Expansion

Circulating erythropoietin is roughly tenfold higher than in matched controls after adjusting for hemoglobin, yet the response to acute hypoxia is identical to normal, so the axis is intact and merely reset. Erythroid progenitors expand in marrow and, at least in the mouse model, in spleen. Erythroid progenitors from R200W homozygotes are additionally hypersensitive to erythropoietin, an asymmetry that is not shared by the Croatian H191D genotype. Note the discriminator from polycythemia vera: white cell and platelet counts are normal, indeed often lower than controls, rather than expanded.

erythroid progenitor cell CL:0000038 kidney interstitial fibroblast CL:1000692

erythrocyte differentiation GO:0030218 ↑ INCREASED

bone marrow UBERON:0002371 kidney UBERON:0002113

Downstream

Increased Circulating Hemoglobin Concentration Erythroid expansion raises hemoglobin from early life.

Increased Hematocrit Erythroid expansion raises hematocrit from early life.

Elevated Circulating Erythropoietin Concentration Erythropoietin is inappropriately high or high-normal for the hemoglobin.

Headache Hyperviscosity from the expanded red cell mass contributes to chronic headache.

Fatigue Chronic symptom burden includes fatigue.

Show evidence (3 references)

PMID:14726398 SUPPORT Human Clinical

"Although hemoglobin-adjusted serum erythropoietin concentrations were approximately 10-fold higher in VHL 598C>T homozygotes than in controls, erythropoietin response to hypoxia was identical."

Quantifies the erythropoietin elevation and shows the hypoxic response is preserved, so the axis is reset rather than broken.

PMID:9058738 SUPPORT Human Clinical

"while platelet and white blood cell counts were normal"

Normal platelet and white cell counts alongside the marked erythrocytosis are the bedside discriminator from the trilineage expansion of polycythemia vera. The hemoglobin figure of 22.6 g/dL sits in the same sentence of the abstract but is followed by a square-bracketed abbreviation that the snippet validator strips, so the quote stops before it.

PMID:23403324 SUPPORT Human Clinical

"We show that erythropoietin levels in homozygous VHL H191D individuals are higher than in VHL R200W patients of similar ages, and their native erythroid progenitors, unlike Chuvash R200W, are not hypersensitive to erythropoietin."

Establishes erythropoietin hypersensitivity of R200W erythroid progenitors by contrast with the H191D genotype.

Prothrombotic State

Thrombosis is the leading cause of morbidity and mortality, and this node is where the disease defies the obvious intuition. The reflex reading is high hematocrit, viscous blood, clots. In Chuvash erythrocytosis that is wrong. In 155 patients followed prospectively against 154 matched controls for eleven years, thrombotic risk rose 8.9-fold, and erythropoietin elevation, not hematocrit and not ferritin, is what correlated with it. Elevated transferrin was, unexpectedly, protective. Contributory mediators include raised plasminogen activator inhibitor-1, vascular endothelial growth factor, and endothelin-1, with a broadly prothrombotic transcriptional milieu. Model the causal edge as HIF and erythropoietin signaling to the prothrombotic state, with erythrocytosis as a parallel consequence rather than the intermediate.

blood coagulation GO:0007596 ↑ INCREASED

Downstream

Arterial Thrombosis The prothrombotic state manifests as arterial thrombotic events.

Venous Thrombosis The prothrombotic state manifests as venous thrombotic events.

Stroke Cerebral vascular events are the leading contributor to premature mortality.

Show evidence (3 references)

PMID:37435906 SUPPORT Human Clinical

"During 11 years of follow-up, risk of thrombosis increased 8.9-fold in patients versus controls. Erythropoietin elevation, but not hematocrit or ferritin, correlated with thrombosis risk."

The central prospective finding: an 8.9-fold thrombotic risk that tracks erythropoietin and not hematocrit.

PMID:30872370 SUPPORT Human Clinical

"We review studies indicating that the occurrence of thrombosis in Chuvash erythrocytosis is independent of hematocrit, that the thrombotic risk is paradoxically increased by phlebotomy in Chuvash erythrocytosis, and that, when compared to chemotherapy, phlebotomy is associated with increased..."

States both halves of the finding: thrombosis independent of hematocrit, and paradoxically increased by phlebotomy.

PMID:16673284 SUPPORT Human Clinical

"Matched-cohort and case-control analyses have shown that VHL 598C> T homozygosity is associated with lower peripheral blood pressures, varicose veins, vertebral hemangiomas, lower white blood cell and platelet counts, and elevated serum concentrations of vascular endothelial growth factor and..."

Documents the elevated plasminogen activator inhibitor-1 and vascular endothelial growth factor that contribute to the prothrombotic milieu.

Pulmonary Vascular Tone and Remodeling

Basal pulmonary vascular tone is elevated and the hypoxic pulmonary vasoconstrictive response is greatly exaggerated, alongside raised basal ventilation, a physiological picture indistinguishable from acclimatization to high altitude. Roughly a third of patients have mild pulmonary hypertension by echocardiography, and tricuspid regurgitation velocity remains elevated after adjusting for blood-volume surrogates, so this is not simply a volume effect. The mouse model settles the causal question: pulmonary hypertension develops independently of the polycythemia, with vascular remodeling, hemorrhage, edema, and macrophage infiltration, all suppressed by Hif2a heterozygosity. Endothelin-1 is elevated in patients and is a HIF target.

pulmonary artery smooth muscle cell CL:0002591

pulmonary vasoconstriction GO:0042310 ↑ INCREASED

pulmonary artery UBERON:0002012

Animal models

VhlR200W knock-in mouse Mouse recapitulates The mouse develops pulmonary hypertension independently of the polycythemia, with vascular remodeling, hemorrhage, edema, and macrophage infiltration, and Hif2a heterozygosity suppresses it. This is what establishes the pulmonary arm as a parallel branch rather than a consequence of the raised hematocrit.

Downstream

Pulmonary Arterial Hypertension Elevated tone and vascular remodeling raise pulmonary artery pressure.

Exercise Intolerance Elevated pulmonary vascular tone contributes to reduced exercise capacity.

Show evidence (4 references)

PMID:16768548 SUPPORT Human Clinical

"Basal ventilation and pulmonary vascular tone were elevated, and ventilatory, pulmonary vasoconstrictive, and heart rate responses to acute hypoxia were greatly increased."

Direct physiological measurement of elevated basal pulmonary vascular tone and exaggerated hypoxic vasoconstriction in patients.

PMID:16769575 SUPPORT Human Clinical

"Plasma endothelin-1 (p=0.010), VEGF (p=0.022) and erythropoietin (p<0.0005) concentrations and Doppler-estimated systolic pulmonary artery pressures (p<0.0005) were higher in the patients while systolic systemic blood pressures were lower (p=0.001)."

Links elevated endothelin-1, a HIF target, to raised pulmonary artery pressure in patients.

PMID:20197624 SUPPORT Model Organism

"These mice developed pulmonary hypertension independently of polycythemia and enhanced normoxic respiration similar to Chuvash patients, further validating VhlR/R mice as a model for Chuvash disease."

Establishes that the pulmonary phenotype is not secondary to the polycythemia, which is what justifies modeling it as a parallel branch.

+ 1 more reference

Hepcidin Suppression and Iron Mobilization

Hepcidin, the master regulator of iron export, is suppressed roughly threefold in homozygotes, and the suppression survives adjustment for both erythropoietin and ferritin, so it is a direct consequence of the raised hypoxic response rather than a downstream effect of accelerated erythropoiesis. Transferrin and transferrin receptor are induced as HIF targets. The clinically important interaction is iatrogenic: therapeutic phlebotomy drives iron deficiency on top of this program, and lower ferritin independently predicts higher pulmonary artery pressure.

Downstream

Decreased Circulating Ferritin Concentration HIF-driven iron mobilization compounded by therapeutic phlebotomy lowers ferritin.

Pulmonary Vascular Tone and Remodeling Lower ferritin independently predicts higher tricuspid regurgitation velocity, so iron depletion feeds back onto the pulmonary vascular node.

Show evidence (2 references)

PMID:21876117 SUPPORT Human Clinical

"After adjustment for serum erythropoietin and ferritin concentrations by multiple linear regression, the geometric mean (95% confidence interval of mean) hepcidin concentration was 8.1 (6.3-10.5) ng/mL in VHL(R200W) homozygotes versus 26.9 (18.6-38.0) ng/mL in controls (P < .001)."

Quantifies hepcidin suppression after adjustment for erythropoietin and ferritin, establishing it as a direct consequence of the hypoxic response.

PMID:21993671 SUPPORT Human Clinical

"Among VHL(R200W) homozygotes, phlebotomy therapy was associated with lower serum ferritin concentration, and low ferritin independently predicted higher tricuspid regurgitation velocity (standardized beta=0.29; P=0.009)."

Establishes the iron-to-pulmonary-pressure link and its iatrogenic driver.

Metabolic Reprogramming Toward Glycolysis

Raised HIF activity induces glycolytic enzymes and pyruvate dehydrogenase kinase, shifting substrate use away from oxidative phosphorylation. During exercise this shows up as early phosphocreatine depletion and acidosis in skeletal muscle, greater blood lactate accumulation, and reduced maximum exercise capacity, with elevated muscle transcripts for pyruvate dehydrogenase kinase, phosphofructokinase, and muscle pyruvate kinase. This is the physiological substrate of the fatigue and exercise limitation patients report, and it is a rare opportunity to observe HIF-driven metabolic regulation at whole-organism level in humans.

glycolytic process GO:0006096 ↑ INCREASED

Downstream

Exercise Intolerance Early muscle acidosis and phosphocreatine depletion reduce maximum exercise capacity.

Fatigue The metabolic shift contributes to the chronic fatigue reported by patients.

Show evidence (2 references)

PMID:20616028 SUPPORT Human Clinical

"During exercise, CP patients had early and marked phosphocreatine depletion and acidosis in skeletal muscle, greater accumulation of lactate in blood, and reduced maximum exercise capacities."

Documents the metabolic phenotype during exercise in patients.

PMID:20616028 SUPPORT Human Clinical

"Muscle biopsy specimens from CP patients showed elevated levels of transcript for pyruvate dehydrogenase kinase, phosphofructokinase, and muscle pyruvate kinase."

Provides the transcriptional basis for the glycolytic shift in patient muscle.

Increased Solid Organ Size

Liver, spleen, and kidney volumes relative to body mass are larger in homozygotes than in matched Chuvash controls. The proposed mechanism runs through the opposing effects of the two HIF isoforms on proliferation: HIF-1-alpha induces the cyclin-dependent kinase inhibitor p21, while HIF-2-alpha promotes MYC activity and proliferation, and mouse data implicate raised hepatic HIF-2-alpha with reduced p21.

spleen UBERON:0002106

Downstream

Splenomegaly Splenic volume is increased relative to body mass.

Show evidence (2 references)

PMID:20140661 SUPPORT Human Clinical

"Here we report that the volumes of liver, spleen, and kidneys relative to body mass were larger in 30 individuals with Chuvash polycythemia than in 30 matched Chuvash controls."

Documents the organ enlargement in a matched human cohort.

PMID:20140661 SUPPORT Model Organism

"At least in the liver, this phenotype may result from increased HIF-2alpha and decreased p21(Cip1) levels leading to increased hepatocyte proliferation."

Offers the proposed HIF-2-alpha and p21 mechanism. PARTIAL because the authors themselves frame it as a hypothesis supported by mouse data.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

15

Cardiovascular 5

Stroke HP:0001297

Show evidence (1 reference)

PMID:14726398 SUPPORT Human Clinical

"In this matched cohort study, VHL 598C>T homozygosity was associated with vertebral hemangiomas, varicose veins, lower blood pressures, and elevated serum vascular endothelial growth factor (VEGF) concentrations (P <.0005), as well as premature mortality related to cerebral vascular events and..."

Links cerebral vascular events to premature mortality in the matched cohort.

Pulmonary Arterial Hypertension FREQUENT HP:0002092

Show evidence (2 references)

PMID:16769575 SUPPORT Human Clinical

"Five (36%) patients and no controls had mild pulmonary hypertension defined as systolic pulmonary artery pressure (c) 35 mmHg."

36% of 14 patients versus none of 14 controls, within the FREQUENT band of 30 to 79%.

PMID:21993671 SUPPORT Human Clinical

"The age-adjusted mean ± SE tricuspid regurgitation velocity was higher in VHL(R200W) homozygotes than controls with normal VHL alleles (2.5±0.03 vs. 2.3±0.05 m/sec, P=0.005)."

Confirms elevated estimated pulmonary artery pressure in a larger cohort of 120 homozygotes.

Varicose Veins HP:0002619

Show evidence (1 reference)

PMID:14726398 SUPPORT Human Clinical

"In this matched cohort study, VHL 598C>T homozygosity was associated with vertebral hemangiomas, varicose veins, lower blood pressures, and elevated serum vascular endothelial growth factor (VEGF) concentrations (P <.0005), as well as premature mortality related to cerebral vascular events and..."

Lists varicose veins among the genotype-associated vascular abnormalities.

Hemangioma HP:0001028

Show evidence (1 reference)

PMID:14726398 SUPPORT Human Clinical

"In this matched cohort study, VHL 598C>T homozygosity was associated with vertebral hemangiomas, varicose veins, lower blood pressures, and elevated serum vascular endothelial growth factor (VEGF) concentrations (P <.0005), as well as premature mortality related to cerebral vascular events and..."

Documents vertebral hemangiomas as a genotype-associated finding.

Splenomegaly HP:0001744

Show evidence (1 reference)

PMID:20140661 SUPPORT Human Clinical

"Here we report that the volumes of liver, spleen, and kidneys relative to body mass were larger in 30 individuals with Chuvash polycythemia than in 30 matched Chuvash controls."

Documents increased splenic volume in a matched cohort of 30 patients.

Nervous System 1

Headache HP:0002315

Temporal: CHRONIC

Show evidence (1 reference)

PMID:37435906 SUPPORT Human Clinical

"Phlebotomies reduce hematocrit and hyperviscosity symptoms."

Establishes hyperviscosity symptoms as a treated feature of the disease. PARTIAL because headache is not named individually in this source.

Constitutional 2

Exercise Intolerance HP:0003546

Show evidence (1 reference)

PMID:20616028 SUPPORT Human Clinical

"During exercise, CP patients had early and marked phosphocreatine depletion and acidosis in skeletal muscle, greater accumulation of lactate in blood, and reduced maximum exercise capacities."

Directly measures reduced maximum exercise capacity with its metabolic correlates.

Fatigue HP:0012378

Temporal: CHRONIC

Show evidence (1 reference)

PMID:20616028 SUPPORT Human Clinical

"During exercise, CP patients had early and marked phosphocreatine depletion and acidosis in skeletal muscle, greater accumulation of lactate in blood, and reduced maximum exercise capacities."

Provides the objective metabolic substrate for exertional fatigue. PARTIAL because fatigue as a reported symptom is not itself measured here.

Other 7

Increased Circulating Hemoglobin Concentration HP:0001900

Show evidence (1 reference)

PMID:9058738 SUPPORT Human Clinical

"Hemoglobins were markedly elevated in the index subjects"

Documents marked hemoglobin elevation in affected subjects under 20 years old. The reported mean of 22.6 g/dL immediately follows in the abstract but is bracketed by an abbreviation the snippet validator strips, so the quote stops short of it.

Increased Hematocrit HP:0001899

Show evidence (1 reference)

PMID:37435906 SUPPORT Human Clinical

"Homozygous VHLR200W results in accumulation of HIFs that increase transcription of the erythropoietin gene and raise hematocrit."

States the mechanistic route from the genotype to the raised hematocrit.

Elevated Circulating Erythropoietin Concentration HP:0033644

Show evidence (1 reference)

PMID:14726398 SUPPORT Human Clinical

"Although hemoglobin-adjusted serum erythropoietin concentrations were approximately 10-fold higher in VHL 598C>T homozygotes than in controls, erythropoietin response to hypoxia was identical."

Quantifies the erythropoietin elevation against matched controls.

Arterial Thrombosis HP:0004420

Show evidence (1 reference)

PMID:16673284 SUPPORT Human Clinical

"These studies have also shown associations with arterial and venous thrombosis, major bleeding episodes, cerebral vascular events, and premature mortality."

Documents arterial thrombosis among the vascular complications established by matched-cohort and case-control analysis.

Venous Thrombosis HP:0004936

Show evidence (2 references)

PMID:16673284 SUPPORT Human Clinical

"These studies have also shown associations with arterial and venous thrombosis, major bleeding episodes, cerebral vascular events, and premature mortality."

Documents venous thrombosis among the established vascular complications.

PMID:37435906 SUPPORT Human Clinical

"During 11 years of follow-up, risk of thrombosis increased 8.9-fold in patients versus controls."

Quantifies the prospective thrombotic risk against matched controls.

Low-To-Normal Blood Pressure HP:0002632

Show evidence (1 reference)

PMID:16769575 SUPPORT Human Clinical

"Plasma endothelin-1 (p=0.010), VEGF (p=0.022) and erythropoietin (p<0.0005) concentrations and Doppler-estimated systolic pulmonary artery pressures (p<0.0005) were higher in the patients while systolic systemic blood pressures were lower (p=0.001)."

Reports significantly lower systolic systemic blood pressures in patients.

Decreased Circulating Ferritin Concentration HP:0012343

Show evidence (2 references)

PMID:37435906 SUPPORT Human Clinical

"Baseline transferrin was elevated, and ferritin reduced in patients."

Documents reduced ferritin with elevated transferrin at steady state.

PMID:21993671 SUPPORT Human Clinical

"Among VHL(R200W) homozygotes, phlebotomy therapy was associated with lower serum ferritin concentration, and low ferritin independently predicted higher tricuspid regurgitation velocity (standardized beta=0.29; P=0.009)."

Attributes the ferritin fall to phlebotomy and links it to raised pulmonary artery pressure.

🧬

Genetic Associations

3

VHL c.598C>T (p.Arg200Trp) Homozygosity

Gene: VHL hgnc:12687 relationship_type: CAUSATIVE variant_origin: GERMLINE

Show evidence (2 references)

PMID:12415268 SUPPORT Human Clinical

"The gene associated with von Hippel-Lindau syndrome, VHL, maps to this region, and homozygosity with respect to a C-->T missense mutation in VHL, causing an arginine-to-tryptophan change at amino-acid residue 200 (Arg200Trp), was identified in all individuals affected with Chuvash polycythemia."

Establishes homozygosity for VHL R200W in all affected individuals.

PMID:16768548 SUPPORT Human Clinical

"Chuvash polycythaemia has recently been defined as a new form of VHL-associated disease, distinct from the classical VHL-associated inherited cancer syndrome, in which germline homozygosity for a hypomorphic VHL allele causes a generalised abnormality in VHL-HIF signalling."

States explicitly that the causative allele is hypomorphic, which is the basis for separating this disease from the VHL cancer syndrome.

EPO Promoter Variant rs1617640

Gene: EPO hgnc:3415 relationship_type: MODIFIER variant_origin: GERMLINE

Show evidence (1 reference)

PMID:37435906 SUPPORT Human Clinical

"The A allele of the promoter EPO single nucleotide polymorphisms (SNP), rs1617640, associated with elevated erythropoietin and increased thrombosis risk, whereas the A allele of the intronic TF SNP, rs3811647, associated with higher transferrin and protection from thrombosis in patients."

Establishes the risk-increasing direction of the EPO promoter variant in patients.

TF Intronic Variant rs3811647

Gene: TF hgnc:11740 relationship_type: MODIFIER variant_origin: GERMLINE

Show evidence (1 reference)

PMID:37435906 SUPPORT Human Clinical

"The A allele of the promoter EPO single nucleotide polymorphisms (SNP), rs1617640, associated with elevated erythropoietin and increased thrombosis risk, whereas the A allele of the intronic TF SNP, rs3811647, associated with higher transferrin and protection from thrombosis in patients."

Establishes the protective direction of the transferrin variant in patients.

💊

Medical Actions

5

Therapeutic Phlebotomy

Action: phlebotomy Ontology label: Phlebotomy NCIT:C28221

The contested standard of care. Phlebotomy reliably reduces hematocrit and relieves hyperviscosity symptoms, and that is the whole of its demonstrated benefit. Against it: it causes iron deficiency, low ferritin independently predicts higher pulmonary artery pressure, and thrombotic risk is paradoxically increased by phlebotomy in this disease. Current expert opinion is that cytoreductive therapy should be avoided and phlebotomy is seldom warranted, with frequency set by symptom control rather than a hematocrit threshold. This is the rare treatment whose target node and harm node are different nodes, and the entry models it that way.

Mechanism Target:

INHIBITS Erythropoietin Excess and Erythroid Expansion — Phlebotomy removes red cell mass, lowering hematocrit and relieving hyperviscosity symptoms. It acts on the erythroid output, not on the prothrombotic node that determines outcome.

Show evidence (4 references)

PMID:37435906 SUPPORT Human Clinical

"Phlebotomies reduce hematocrit and hyperviscosity symptoms."

States the demonstrated benefit of phlebotomy, which is symptomatic.

PMID:30872370 REFUTE Human Clinical

"We review studies indicating that the occurrence of thrombosis in Chuvash erythrocytosis is independent of hematocrit, that the thrombotic risk is paradoxically increased by phlebotomy in Chuvash erythrocytosis, and that, when compared to chemotherapy, phlebotomy is associated with increased..."

Refutes the thrombosis-prevention rationale for phlebotomy and reports the opposite association.

PMID:21993671 REFUTE Human Clinical

"Among VHL(R200W) homozygotes, phlebotomy therapy was associated with lower serum ferritin concentration, and low ferritin independently predicted higher tricuspid regurgitation velocity (standardized beta=0.29; P=0.009)."

Documents the second harm route, phlebotomy-induced iron deficiency raising estimated pulmonary artery pressure.

+ 1 more reference

Low-Dose Aspirin

Action: Pharmacotherapy NCIT:C15986

Agent: acetylsalicylic acid CHEBI:15365

Widely advised on general cardiovascular grounds, and not demonstrated to benefit this disease specifically. Retrospective analyses have not shown benefit for either phlebotomy or aspirin, and the authors of those analyses call for prospective study.

Show evidence (2 references)

PMID:16673284 NO_EVIDENCE Human Clinical

"Retrospective analyses among patients with Chuvash polycythemia have not shown benefit for therapy with phlebotomy or aspirin, but these and other modes of therapy should be studied prospectively."

Reports the absence of demonstrated benefit for aspirin in retrospective analysis, without establishing harm.

PMID:34021251 SUPPORT Human Clinical

"Although not supported by hard evidence, cardiovascular risk optimization and low-dose aspirin use are often advised."

Records that aspirin is commonly advised while stating that hard evidence is lacking, which is exactly the epistemic status this entry assigns it.

Anticoagulation for Documented Thrombosis

Action: anticoagulation therapy Ontology label: Anticoagulation Therapy NCIT:C63341

Anticoagulation is used for treatment and secondary prevention of documented thrombotic events, following general thrombosis practice rather than any disease-specific evidence. There is no controlled evidence on primary thromboprophylaxis in this disease, which is a conspicuous gap given that thrombosis is what kills people.

Show evidence (1 reference)

PMID:16673284 SUPPORT Human Clinical

"These studies have also shown associations with arterial and venous thrombosis, major bleeding episodes, cerebral vascular events, and premature mortality."

Establishes the thrombotic burden that motivates anticoagulation. PARTIAL because it also documents major bleeding episodes, so the risk-benefit balance is not settled, and no anticoagulation trial exists in this disease.

HIF-2-alpha Inhibition

Action: Pharmacotherapy NCIT:C15986

Agent: belzutifan NCIT:C135627

The mechanism-matched therapy, and the most interesting open question in the disease. The second-generation allosteric HIF-2-alpha inhibitor belzutifan decreased erythropoietin production and reversed polycythemia in three relevant mouse models, and also lowered right ventricular pressure and mitigated pulmonary hypertension to near wild-type levels. The evidence is preclinical. There is a published human case of response in congenital polycythemia, but it is a single compound heterozygote rather than an R200W homozygote, and the cached record for that report carries no abstract text, so it is recorded in notes rather than cited as evidence here.

Mechanism Target:

INHIBITS Normoxic HIF-alpha Stabilization — Allosteric inhibition of HIF-2-alpha blocks the dominant effector isoform at the node where the disease originates, rather than downstream of it.

Show evidence (2 references)

PMID:33512384 SUPPORT Model Organism

"MK-6482 treatment decreased EPO production and reversed polycythemia in all 3 mouse models."

Establishes reversal of the erythroid phenotype by HIF-2-alpha inhibition in the knock-in mouse and two related models.

PMID:33512384 SUPPORT Model Organism

"Drug treatment also decreased right ventricular pressure and mitigated pulmonary hypertension in VhlR200W, Irp1-KO, and VhlR200W;Irp1-KO mice to near normal wild-type levels and normalized the movement of the cardiac interventricular septum in VhlR200Wmice."

Extends the preclinical benefit to the pulmonary vascular arm.

Tempol (IRP1-Mediated HIF-2-alpha Repression)

Action: Pharmacotherapy NCIT:C15986

A mouse-only strategy that works by a different route to the same target. Dietary Tempol increases the iron-responsive-element binding activity of Irp1, which translationally represses Hif2a. In VhlR200W mice it decreased erythropoietin production, corrected splenomegaly, normalized hematocrit, and increased lifespan, and the effect was abolished when Irp1 was genetically ablated, which is a clean demonstration that the mechanism is the one proposed. No human data exist.

Mechanism Target:

INHIBITS Normoxic HIF-alpha Stabilization — Tempol represses HIF-2-alpha translationally through Irp1, lowering the stabilized HIF-2-alpha pool. Demonstrated only in mice.

Show evidence (2 references)

PMID:29480820 SUPPORT Model Organism

"Here, we fed VhlR200W mice supplemented with Tempol, a small, stable nitroxide molecule and observed that Tempol decreased erythropoietin production, corrected splenomegaly, normalized hematocrit levels, and increased the lifespans of these mice."

Documents the preclinical benefit including a survival effect.

PMID:29480820 SUPPORT Model Organism

"We attribute the reversal of erythrocytosis/polycythemia to translational repression of Hif2α expression by Tempol-mediated increases in the IRE-binding activity of Irp1, as reversal of polycythemia was abrogated in VhlR200W mice in which Irp1 was genetically ablated."

The Irp1-knockout abrogation establishes that the benefit runs through the proposed mechanism.

🔬

Biochemical Markers

2

Suppressed Serum Hepcidin (DECREASED)

Context: Serum hepcidin is about threefold lower in homozygotes than controls after adjustment for erythropoietin and ferritin, and no independent relationship of erythropoietin, hemoglobin, or red cell count with hepcidin was found. That adjustment is the point: hepcidin suppression here is a direct consequence of the raised hypoxic response rather than a downstream effect of accelerated erythropoiesis, which is a genuinely informative dissociation for iron biology generally.

Show evidence (1 reference)

PMID:21876117 SUPPORT Human Clinical

"In contrast, a significant independent relationship of serum erythropoietin, hemoglobin, or RBC count with hepcidin was not observed."

Establishes that the hepcidin suppression is independent of erythropoietin and red cell mass.

Elevated Serum Transferrin (INCREASED)

Context: Transferrin is elevated as a HIF target and further raised by iron deficiency. The clinically surprising part is its direction of association: transferrin elevation was associated with reduced rather than increased thrombosis risk, and the A allele of the intronic TF variant rs3811647 associated with higher transferrin and protection from thrombosis. The investigators say plainly that they did not expect this.

Show evidence (2 references)

PMID:37435906 SUPPORT Human Clinical

"Unexpectedly, transferrin elevation associated with reduced rather than increased thrombosis risk."

The protective direction of the transferrin association, stated by the authors as unexpected.

PMID:37435906 SUPPORT Human Clinical

"The A allele of the promoter EPO single nucleotide polymorphisms (SNP), rs1617640, associated with elevated erythropoietin and increased thrombosis risk, whereas the A allele of the intronic TF SNP, rs3811647, associated with higher transferrin and protection from thrombosis in patients."

Provides the genetic modifier evidence supporting both the risk and protective directions.

🔬

Diagnosis

3

Diagnostic Workup for Congenital Erythrocytosis

Confirm persistent erythrocytosis, then exclude polycythemia vera (JAK2 unmutated; and note that white cell and platelet counts are normal or low here rather than expanded), exclude acquired secondary causes such as cardiopulmonary disease, high-altitude residence, sleep apnea, renal artery stenosis, and erythropoiesis-stimulating agents, then measure erythropoietin (high or inappropriately normal, and a normal value does not exclude the diagnosis) and p50 (normal here, left-shifted in high-affinity hemoglobinopathies), then confirm genetically.

Show evidence (2 references)

PMID:34021251 SUPPORT Human Clinical

"Workup for hereditary/congenital erythrocytosis requires documentation of family history and laboratory screening for high-oxygen affinity hemoglobin variants, 2, 3 biphosphoglycerate deficiency, and germline mutations that are known to alter cellular oxygen sensing (e.g., PHD2, HIF2A, VHL) or..."

Sets out the diagnostic algorithm for congenital erythrocytosis including the VHL oxygen-sensing route.

PMID:9058738 SUPPORT Human Clinical

"Familial and congenital polycythemia, not due to high oxygen affinity hemoglobin or reduced 2,3-diphosphoglycerate in erythrocytes, is common in the Chuvash population of the Russian Federation."

Establishes normal oxygen affinity and normal 2,3-diphosphoglycerate as part of the diagnostic signature.

VHL Genetic Testing

Targeted single-variant testing for VHL c.598C>T is efficient where the allele is common; otherwise a congenital erythrocytosis gene panel covering VHL, EPAS1, EGLN1, EPOR, the globin genes, and BPGM, escalating to exome or genome sequencing. A coding-exon-only assay can miss splice-altering variants including those in a cryptic intron-1 exon, so a clean coding VHL result in a high-suspicion case is a reason to look further rather than to stop.

Show evidence (4 references)

PMID:37362405 SUPPORT Human Clinical

"Despite a lower frequency (8%) compared to literature, our results suggest that the relatively simpler PCR-RFLP for VHL:c.598C > T mutation may be considered for the initial genetic screening of unexplained, suspected congenital erythrocytosis in regions where Chuvash polycythemia comprises a..."

Supports targeted single-variant PCR-RFLP as a first-line genetic screen where the allele is common, and states the prerequisite exclusions.

PMID:29891534 SUPPORT Human Clinical

"Here, we identify a new VHL cryptic exon (termed E1') deep in intron 1 that is naturally expressed in many tissues."

Identifies the intron-1 cryptic exon that a coding-exon-only assay cannot see.

PMID:29891534 SUPPORT Human Clinical

"In addition, we demonstrate a pathogenic role for synonymous mutations in VHL exon 2 that altered splicing through E2-skipping in 5 families with erythrocytosis or VHL disease."

Establishes that synonymous coding variants can be pathogenic through splicing, so a clean coding readout does not exclude the diagnosis.

+ 1 more reference

Echocardiographic Screening for Pulmonary Hypertension

Doppler echocardiography with tricuspid regurgitation velocity, interpreted with the caveat that this measure is influenced by blood volume and iron status. In the largest cohort the elevation persisted after adjustment for left ventricular diastolic and left atrial diameters, so it is not merely a volume artifact.

Show evidence (1 reference)

PMID:21993671 SUPPORT Human Clinical

"The age-adjusted left ventricular diastolic diameter (4.8±0.05 vs. 4.5±0.09 cm, P=0.005) and left atrial diameter (3.4±0.04 vs. 3.2±0.08 cm, P=0.011) were also greater in the VHL(R200W) homozygotes, consistent with increased blood volume, but the elevation in tricuspid regurgitation velocity..."

Documents both the confound and the adjustment that survives it.

📈

Progression

2

Congenital and childhood

Erythrocytosis is present from birth or infancy and is often documented in childhood; the six index subjects in the original Chuvash series were all under 20 years old. Onset is insidious rather than acute, and there is no presenting event.

Show evidence (1 reference)

PMID:9058738 SUPPORT Human Clinical

"We studied six polycythemic Chuvash patients <20 years of age from unrelated families and 12 first-degree family members."

Establishes that the phenotype is present and detectable in childhood and adolescence.

Adult event-driven course

Hematologically the disease is stable or slowly progressive; clinically it is event-driven, punctuated by discrete thrombotic and cerebrovascular events that accumulate with age and produce premature mortality. Pulmonary artery pressure is a progressive variable that is modifiable by iron status.

Show evidence (1 reference)

PMID:14726398 SUPPORT Human Clinical

"In this matched cohort study, VHL 598C>T homozygosity was associated with vertebral hemangiomas, varicose veins, lower blood pressures, and elevated serum vascular endothelial growth factor (VEGF) concentrations (P <.0005), as well as premature mortality related to cerebral vascular events and..."

Establishes the event-driven vascular course and its contribution to premature mortality.

📊

Prevalence

2

Island of Ischia, Campania, Italy (allele frequency)

Carrier Frequency 7000.0 per 100,000 >1 in 1,000

Mutated allele frequency 0.070 on Ischia versus 0.057 in Chuvashia. Recorded here as an allele frequency, expressed per 100,000 alleles, not as a disease prevalence. Deriving a homozygote prevalence from these by Hardy-Weinberg would be arithmetic rather than a published figure and is deliberately not done.

Show evidence (1 reference)

PMID:16210343 SUPPORT Human Clinical

"From analysis of the mutated allele, we found that the disease was more frequent on Ischia (0.070) than in Chuvashia (0.057)."

Gives the mutated allele frequencies for both endemic clusters.

Worldwide

Point Prevalence Unknown

Orphanet records the worldwide point prevalence for Chuvash erythrocytosis as unknown and not yet validated, and no published incidence figure was found. The disease is qualitatively described as affecting hundreds of individuals in Chuvashia and as the only endemic form of familial and congenital polycythemia described. Recording UNKNOWN rather than inventing a number.

Show evidence (1 reference)

PMID:9058738 SUPPORT Human Clinical

"Hundreds of individuals appear to be affected in an autosomal recessive pattern."

A qualitative statement of case load in the endemic region. PARTIAL because it supports no numeric prevalence estimate.

⚖️

Clinical Burden

High

Thrombosis and cerebrovascular events drive premature mortality, with an 8.9-fold increase in thrombotic risk over eleven years of prospective follow-up against matched controls. Chronic headache, fatigue, and reduced exercise capacity persist between events, and about a third of patients carry mild pulmonary hypertension. Notably absent is any excess cancer risk, despite the causative gene being a tumor suppressor. There is no therapy of demonstrated benefit, and the standard of care, phlebotomy, is itself associated with increased thrombotic risk and with higher pulmonary artery pressure through iron depletion.

Show evidence (2 references)

PMID:37435906 SUPPORT Human Clinical

"However, the major cause of morbidity and mortality in Chuvash erythrocytosis is thrombosis."

Identifies thrombosis as the dominant source of morbidity and mortality.

PMID:16673284 SUPPORT Human Clinical

"Spinocerebellar hemangioblastomas, renal carcinomas, and pheochromocytomas typical of classical VHL tumor predisposition syndrome have not been found, and no increased risk of cancer has been demonstrated."

Establishes the absence of demonstrated excess cancer risk, which materially changes the burden profile relative to classical VHL syndrome.

🔀

Differential Diagnoses

4

Conditions with similar clinical presentations that must be differentiated from Chuvash Polycythemia:

Polycythemia Vera

Overlapping Features The principal differential and the one whose management rules must not be carried over. Polycythemia vera is an acquired JAK2-mutated myeloproliferative neoplasm with trilineage expansion and low erythropoietin. Chuvash erythrocytosis is congenital, JAK2-unmutated, has high or inappropriately-normal erythropoietin, and has normal or low white cell and platelet counts. Applying the polycythemia vera hematocrit target here is the specific error the recent literature warns against.

Distinguishing Features

JAK2 V617F or exon 12 mutation present in polycythemia vera, absent here
Erythropoietin low in polycythemia vera, high or inappropriately normal here
Leukocytosis and thrombocytosis in polycythemia vera; normal or low counts here
Acquired adult onset versus congenital lifelong erythrocytosis

Show evidence (1 reference)

PMID:9058738 SUPPORT Human Clinical

"while platelet and white blood cell counts were normal"

The normal platelet and white cell counts are the bedside discriminator from the trilineage expansion of polycythemia vera.

Classical von Hippel-Lindau Syndrome

Overlapping Features Same gene, opposite disease. Classical VHL syndrome is autosomal dominant, tumor-predominant (hemangioblastoma, clear cell renal cell carcinoma, pheochromocytoma), and erythrocytosis is uncommon. Chuvash erythrocytosis is recessive, hypomorphic, and has no demonstrated excess cancer risk. Routine lifelong VHL tumor surveillance is not standard for R200W homozygotes.

Distinguishing Features

Autosomal dominant heterozygous VHL loss versus homozygous hypomorphic R200W
Tumor predisposition versus no demonstrated excess cancer risk
Erythrocytosis uncommon versus obligate

Show evidence (1 reference)

PMID:16673284 SUPPORT Human Clinical

"Spinocerebellar hemangioblastomas, renal carcinomas, and pheochromocytomas typical of classical VHL tumor predisposition syndrome have not been found, and no increased risk of cancer has been demonstrated."

Establishes the absence of the classical VHL tumor spectrum in this disease.

Croatian VHL H191D Homozygous Erythrocytosis

Overlapping Features The other known inherited homozygous VHL erythrocytosis, and phenotypically distinct rather than a variant of the same thing. H191D homozygotes have higher erythropoietin for age, and their erythroid progenitors are not hypersensitive to erythropoietin, unlike R200W. Curating them together would obscure exactly the asymmetry that constrains mechanistic models.

Distinguishing Features

VHL c.571C>G p.His191Asp rather than c.598C>T p.Arg200Trp
Higher erythropoietin levels for age than R200W patients
Erythroid progenitors not hypersensitive to erythropoietin

Show evidence (1 reference)

PMID:23403324 SUPPORT Human Clinical

"We show that erythropoietin levels in homozygous VHL H191D individuals are higher than in VHL R200W patients of similar ages, and their native erythroid progenitors, unlike Chuvash R200W, are not hypersensitive to erythropoietin."

Documents the two phenotypic discriminators between the genotypes.

🐁

Animal Models

1

VhlR200W knock-in mouse

A knock-in mouse homozygous for the same R200W substitution, and the workhorse of the field. It recapitulates the polycythemia, the enhanced normoxic respiration, and the pulmonary hypertension, and it has been the system in which the isoform question, the therapeutic questions, and the pulmonary-versus-erythroid independence question were all settled.

Species

Mouse

Genotype

Vhl R200W homozygous knock-in

Publication

PMID:20197624

Pathograph links

Pulmonary Vascular Tone and Remodeling recapitulates fidelity: high The mouse develops pulmonary hypertension independently of the polycythemia, with vascular remodeling, hemorrhage, edema, and macrophage infiltration, and Hif2a heterozygosity suppresses it. This is what establishes the pulmonary arm as a parallel branch rather than a consequence of the raised hematocrit.

Limitations: Older mice additionally develop pulmonary fibrosis, which is not a documented feature of the human disease, so the model overshoots on that axis. Mouse pulmonary vascular physiology differs from human, and the inflammatory component was not suppressed by Hif2a heterozygosity even though the vascular changes were.

Show evidence (1 reference)

PMID:20197624 SUPPORT Model Organism

"These mice developed pulmonary hypertension independently of polycythemia and enhanced normoxic respiration similar to Chuvash patients, further validating VhlR/R mice as a model for Chuvash disease."

The authors' own validation statement for the model against the human phenotype.

Normoxic HIF-alpha Stabilization perturbs fidelity: high Genetic reduction of Hif2a, but not Hif1a, in this background suppresses both the polycythemia and the pulmonary hypertension, which is the experiment that assigns isoform responsibility.

Limitations: Epistasis in the mouse assigns the dominant effector isoform but does not exclude a HIF-1-alpha contribution to other arms of the human phenotype, notably the metabolic one, and human patients have both isoforms elevated.

Show evidence (1 reference)

PMID:20197624 SUPPORT Model Organism

"HIF-2alpha activity was increased in lungs from VhlR/R mice, and heterozygosity for Hif2a, but not Hif1a, genetically suppressed both the polycythemia and pulmonary hypertension in the VhlR/R mice."

The genetic epistasis result establishing HIF-2-alpha as the dominant effector.

{ }

Source YAML

click to show

name: Chuvash Polycythemia
creation_date: "2026-08-15T00:00:00Z"
category: Mendelian
parents:
- Congenital Secondary Erythrocytosis
- Disorder of Oxygen Sensing
disease_term:
  preferred_term: Chuvash Polycythemia
  term:
    id: MONDO:0009892
    label: Chuvash polycythemia
synonyms:
- Chuvash erythrocytosis
- VHL-related polycythemia
- von Hippel-Lindau-dependent polycythemia
- erythrocytosis, familial, 2
- ECYT2
description: >-
  Chuvash polycythemia is the first recognized congenital disorder of oxygen
  sensing. Homozygosity for a single VHL missense allele, c.598C>T
  (p.Arg200Trp), weakens the grip of the von Hippel-Lindau protein on the
  hypoxia-inducible transcription factors it normally tags for destruction. The
  cell's oxygen thermostat never fully stands down: HIF-1-alpha and HIF-2-alpha
  accumulate at ordinary room air, erythropoietin runs about tenfold high for the
  hemoglobin, red cell mass climbs, pulmonary vascular tone stays elevated, and
  basal ventilation runs fast, all as though the patient lived permanently at
  altitude. Two things make this disease unusual. First, it is a VHL disease that
  does not cause the tumors VHL disease is famous for, because R200W is a
  hypomorph that retains substantial pVHL function including the HIF-independent
  mitochondrial arm. Second, and clinically decisive, the thrombosis that
  dominates morbidity and mortality is not driven by the high hematocrit:
  prospective cohort data show erythropoietin elevation, but not hematocrit,
  correlates with thrombotic risk, and phlebotomy is associated with increased
  rather than decreased risk. Hemoglobin-oxygen affinity is normal, and white
  cell and platelet counts are normal or low, which is what separates this from
  polycythemia vera at the bedside.
pathophysiology:
- name: Impaired pVHL Binding to Hydroxylated HIF-alpha
  biological_scale: MOLECULAR
  description: >-
    pVHL is the substrate-recognition subunit of a Cullin-2 RING E3 ubiquitin
    ligase. Under normal oxygen tension, prolyl hydroxylases hydroxylate
    conserved prolines in HIF-1-alpha and HIF-2-alpha, pVHL binds the
    hydroxyproline, and the HIF-alpha subunit is polyubiquitinated and destroyed
    by the proteasome. The Arg200Trp substitution weakens that interaction. It
    does not abolish it, and that distinction carries the whole disease: a
    hypomorph produces a chronically mis-set oxygen thermostat, where a null
    would produce the tumor syndrome.
  genes:
  - preferred_term: VHL
    term:
      id: hgnc:12687
      label: VHL
  biological_processes:
  - preferred_term: proteasome-mediated degradation of HIF-alpha
    term:
      id: GO:0043161
      label: proteasome-mediated ubiquitin-dependent protein catabolic process
    modifier: DECREASED
  - preferred_term: HIF-alpha ubiquitination
    term:
      id: GO:0016567
      label: protein ubiquitination
    modifier: DECREASED
  downstream:
  - target: Normoxic HIF-alpha Stabilization
    description: >-
      Reduced pVHL binding slows HIF-alpha degradation, so HIF-alpha accumulates
      despite normal oxygen tension.
    causal_link_type: DIRECT
    hypothesis_groups:
    - canonical_hif_stabilization
  evidence:
  - reference: PMID:12415268
    reference_title: Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our data indicate that the Arg200Trp substitution impairs the interaction of VHL with HIF1alpha, reducing the rate of degradation of HIF1alpha and resulting in increased expression of downstream target genes including EPO (encoding erythropoietin), SLC2A1 (also known as GLUT1, encoding solute carrier family 2 (facilitated glucose transporter), member 1), TF (encoding transferrin), TFRC (encoding transferrin receptor (p90, CD71)) and VEGF (encoding vascular endothelial growth factor)."
    explanation: >-
      The discovery paper establishing that R200W impairs pVHL-HIF binding and
      slows HIF-alpha degradation.
  - reference: PMID:37435906
    reference_title: Increased transferrin protects from thrombosis in Chuvash erythrocytosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This mutation impairs binding of VHL to HIF-α subunits and therefore decreases ubiquitin-mediated degradation."
    explanation: >-
      Restates the molecular lesion as impaired binding with consequent reduced
      ubiquitin-mediated degradation.
- name: Normoxic HIF-alpha Stabilization
  biological_scale: MOLECULAR
  description: >-
    HIF-1-alpha and HIF-2-alpha accumulate and dimerize with HIF-1-beta at normal
    oxygen tension. The cell believes it is short of oxygen while sitting in
    ordinary room air, which is why the whole phenotype reads as permanent
    altitude acclimatization. Both isoforms are elevated in patients, but they are
    not interchangeable: mouse genetics show heterozygosity for Hif2a, and not
    Hif1a, suppresses both the polycythemia and the pulmonary hypertension, so
    HIF-2-alpha is the dominant effector for the erythroid and pulmonary-vascular
    arms.
  biological_processes:
  - preferred_term: normoxic hypoxia response
    term:
      id: GO:0001666
      label: response to hypoxia
    modifier: GAIN_OF_FUNCTION
  downstream:
  - target: HIF Target Gene Program Activation
    description: >-
      Stabilized HIF-alpha dimers drive transcription of the hypoxia-response
      program despite normoxia.
    causal_link_type: DIRECT
    hypothesis_groups:
    - canonical_hif_stabilization
  - target: Pulmonary Vascular Tone and Remodeling
    description: >-
      HIF-2-alpha activity drives the pulmonary vascular phenotype, which mouse
      genetics show develops independently of the polycythemia.
    causal_link_type: DIRECT
    hypothesis_groups:
    - canonical_hif_stabilization
  evidence:
  - reference: PMID:21876117
    reference_title: Chuvash polycythemia VHLR200W mutation is associated with down-regulation of hepcidin expression.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "VHL(R200W) homozygotes have elevated hypoxia-inducible factor 1α (HIF-1α) and HIF-2α levels, increased red cell mass, propensity to thrombosis, and early mortality."
    explanation: >-
      Confirms that both HIF-alpha isoforms are elevated in patients, not just
      HIF-1-alpha as the original discovery paper framed it.
  - reference: PMID:20197624
    reference_title: The von Hippel-Lindau Chuvash mutation promotes pulmonary hypertension and fibrosis in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "HIF-2alpha activity was increased in lungs from VhlR/R mice, and heterozygosity for Hif2a, but not Hif1a, genetically suppressed both the polycythemia and pulmonary hypertension in the VhlR/R mice."
    explanation: >-
      Genetic epistasis in the knock-in mouse establishing HIF-2-alpha rather than
      HIF-1-alpha as the dominant effector isoform.
- name: HIF Target Gene Program Activation
  biological_scale: MOLECULAR
  description: >-
    The stabilized HIF dimers transcribe the full hypoxia-response program at
    normal oxygen: erythropoietin, the glucose transporter SLC2A1, transferrin and
    its receptor, vascular endothelial growth factor, and endothelin-1. This is
    the fan-out point of the disease, and it is why a single amino-acid change
    produces phenotypes in blood, lung, vasculature, iron handling, and muscle
    metabolism at once. Note that hypoxic regulation itself remains intact and
    correctly shaped; only the setpoint has moved.
  biological_processes:
  - preferred_term: cellular response to hypoxia
    term:
      id: GO:0071456
      label: cellular response to hypoxia
    modifier: INCREASED
  downstream:
  - target: Erythropoietin Excess and Erythroid Expansion
    description: >-
      Transcriptional induction of EPO raises circulating erythropoietin about
      tenfold for the prevailing hemoglobin.
    causal_link_type: DIRECT
    hypothesis_groups:
    - canonical_hif_stabilization
  - target: Prothrombotic State
    description: >-
      HIF-driven signaling, indexed clinically by the erythropoietin elevation,
      is what tracks thrombotic risk. This edge runs in parallel with the
      erythroid arm rather than through it.
    causal_link_type: DIRECT
    hypothesis_groups:
    - canonical_hif_stabilization
  - target: Hepcidin Suppression and Iron Mobilization
    description: >-
      Transferrin and transferrin receptor induction together with hepcidin
      suppression reconfigure systemic iron handling.
    causal_link_type: DIRECT
  - target: Metabolic Reprogramming Toward Glycolysis
    description: >-
      Induction of glycolytic enzymes and pyruvate dehydrogenase kinase shifts
      substrate use toward glycolysis.
    causal_link_type: DIRECT
  - target: Increased Solid Organ Size
    description: >-
      HIF-2-alpha-driven proliferation with reduced p21 enlarges liver, spleen,
      and kidney relative to body mass.
  evidence:
  - reference: PMID:12415268
    reference_title: Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our data indicate that the Arg200Trp substitution impairs the interaction of VHL with HIF1alpha, reducing the rate of degradation of HIF1alpha and resulting in increased expression of downstream target genes including EPO (encoding erythropoietin), SLC2A1 (also known as GLUT1, encoding solute carrier family 2 (facilitated glucose transporter), member 1), TF (encoding transferrin), TFRC (encoding transferrin receptor (p90, CD71)) and VEGF (encoding vascular endothelial growth factor)."
    explanation: >-
      Enumerates the induced target genes that constitute this node.
  - reference: PMID:14726398
    reference_title: "Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thus, Chuvash polycythemia is a distinct VHL syndrome manifested by thrombosis, vascular abnormalities, and intact hypoxic regulation despite increased basal expression of hypoxia-regulated genes."
    explanation: >-
      Establishes that basal hypoxia-gene expression is raised while hypoxic
      regulation itself remains intact, which is the defining shape of this node.
- name: Erythropoietin Excess and Erythroid Expansion
  biological_scale: TISSUE
  description: >-
    Circulating erythropoietin is roughly tenfold higher than in matched controls
    after adjusting for hemoglobin, yet the response to acute hypoxia is
    identical to normal, so the axis is intact and merely reset. Erythroid
    progenitors expand in marrow and, at least in the mouse model, in spleen.
    Erythroid progenitors from R200W homozygotes are additionally hypersensitive
    to erythropoietin, an asymmetry that is not shared by the Croatian H191D
    genotype. Note the discriminator from polycythemia vera: white cell and
    platelet counts are normal, indeed often lower than controls, rather than
    expanded.
  cell_types:
  - preferred_term: erythroid progenitor cell
    term:
      id: CL:0000038
      label: erythroid progenitor cell
  - preferred_term: kidney interstitial fibroblast
    term:
      id: CL:1000692
      label: kidney interstitial fibroblast
  biological_processes:
  - preferred_term: erythrocyte differentiation
    term:
      id: GO:0030218
      label: erythrocyte differentiation
    modifier: INCREASED
  locations:
  - preferred_term: bone marrow
    term:
      id: UBERON:0002371
      label: bone marrow
  - preferred_term: kidney
    term:
      id: UBERON:0002113
      label: kidney
  downstream:
  - target: Increased Circulating Hemoglobin Concentration
    description: Erythroid expansion raises hemoglobin from early life.
  - target: Increased Hematocrit
    description: Erythroid expansion raises hematocrit from early life.
  - target: Elevated Circulating Erythropoietin Concentration
    description: >-
      Erythropoietin is inappropriately high or high-normal for the hemoglobin.
  - target: Headache
    description: >-
      Hyperviscosity from the expanded red cell mass contributes to chronic
      headache.
  - target: Fatigue
    description: Chronic symptom burden includes fatigue.
  evidence:
  - reference: PMID:14726398
    reference_title: "Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Although hemoglobin-adjusted serum erythropoietin concentrations were approximately 10-fold higher in VHL 598C>T homozygotes than in controls, erythropoietin response to hypoxia was identical."
    explanation: >-
      Quantifies the erythropoietin elevation and shows the hypoxic response is
      preserved, so the axis is reset rather than broken.
  - reference: PMID:9058738
    reference_title: Congenital polycythemia in Chuvashia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "while platelet and white blood cell counts were normal"
    explanation: >-
      Normal platelet and white cell counts alongside the marked erythrocytosis
      are the bedside discriminator from the trilineage expansion of polycythemia
      vera. The hemoglobin figure of 22.6 g/dL sits in the same sentence of the
      abstract but is followed by a square-bracketed abbreviation that the snippet
      validator strips, so the quote stops before it.
  - reference: PMID:23403324
    reference_title: "The phenotype of polycythemia due to Croatian homozygous VHL (571C>G:H191D) mutation is different from that of Chuvash polycythemia (VHL 598C>T:R200W)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We show that erythropoietin levels in homozygous VHL H191D individuals are higher than in VHL R200W patients of similar ages, and their native erythroid progenitors, unlike Chuvash R200W, are not hypersensitive to erythropoietin."
    explanation: >-
      Establishes erythropoietin hypersensitivity of R200W erythroid progenitors
      by contrast with the H191D genotype.
- name: Prothrombotic State
  biological_scale: ORGANISM
  description: >-
    Thrombosis is the leading cause of morbidity and mortality, and this node is
    where the disease defies the obvious intuition. The reflex reading is high
    hematocrit, viscous blood, clots. In Chuvash erythrocytosis that is wrong. In
    155 patients followed prospectively against 154 matched controls for eleven
    years, thrombotic risk rose 8.9-fold, and erythropoietin elevation, not
    hematocrit and not ferritin, is what correlated with it. Elevated transferrin
    was, unexpectedly, protective. Contributory mediators include raised
    plasminogen activator inhibitor-1, vascular endothelial growth factor, and
    endothelin-1, with a broadly prothrombotic transcriptional milieu. Model the
    causal edge as HIF and erythropoietin signaling to the prothrombotic state,
    with erythrocytosis as a parallel consequence rather than the intermediate.
  biological_processes:
  - preferred_term: blood coagulation
    term:
      id: GO:0007596
      label: blood coagulation
    modifier: INCREASED
  downstream:
  - target: Arterial Thrombosis
    description: The prothrombotic state manifests as arterial thrombotic events.
  - target: Venous Thrombosis
    description: The prothrombotic state manifests as venous thrombotic events.
  - target: Stroke
    description: >-
      Cerebral vascular events are the leading contributor to premature
      mortality.
  evidence:
  - reference: PMID:37435906
    reference_title: Increased transferrin protects from thrombosis in Chuvash erythrocytosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "During 11 years of follow-up, risk of thrombosis increased 8.9-fold in patients versus controls. Erythropoietin elevation, but not hematocrit or ferritin, correlated with thrombosis risk."
    explanation: >-
      The central prospective finding: an 8.9-fold thrombotic risk that tracks
      erythropoietin and not hematocrit.
  - reference: PMID:30872370
    reference_title: Re-evaluation of hematocrit as a determinant of thrombotic risk in erythrocytosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We review studies indicating that the occurrence of thrombosis in Chuvash erythrocytosis is independent of hematocrit, that the thrombotic risk is paradoxically increased by phlebotomy in Chuvash erythrocytosis, and that, when compared to chemotherapy, phlebotomy is associated with increased thrombotic risk in polycythemia vera."
    explanation: >-
      States both halves of the finding: thrombosis independent of hematocrit, and
      paradoxically increased by phlebotomy.
  - reference: PMID:16673284
    reference_title: Vascular complications in Chuvash polycythemia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Matched-cohort and case-control analyses have shown that VHL 598C> T homozygosity is associated with lower peripheral blood pressures, varicose veins, vertebral hemangiomas, lower white blood cell and platelet counts, and elevated serum concentrations of vascular endothelial growth factor and plasminogen activator inhibitor-1."
    explanation: >-
      Documents the elevated plasminogen activator inhibitor-1 and vascular
      endothelial growth factor that contribute to the prothrombotic milieu.
- name: Pulmonary Vascular Tone and Remodeling
  biological_scale: TISSUE
  conforms_to: "pulmonary_vascular_remodeling#Pulmonary Artery Smooth Muscle Cell Proliferation and Vasoconstriction"
  description: >-
    Basal pulmonary vascular tone is elevated and the hypoxic pulmonary
    vasoconstrictive response is greatly exaggerated, alongside raised basal
    ventilation, a physiological picture indistinguishable from acclimatization to
    high altitude. Roughly a third of patients have mild pulmonary hypertension by
    echocardiography, and tricuspid regurgitation velocity remains elevated after
    adjusting for blood-volume surrogates, so this is not simply a volume effect.
    The mouse model settles the causal question: pulmonary hypertension develops
    independently of the polycythemia, with vascular remodeling, hemorrhage,
    edema, and macrophage infiltration, all suppressed by Hif2a heterozygosity.
    Endothelin-1 is elevated in patients and is a HIF target.
  cell_types:
  - preferred_term: pulmonary artery smooth muscle cell
    term:
      id: CL:0002591
      label: smooth muscle cell of the pulmonary artery
  biological_processes:
  - preferred_term: pulmonary vasoconstriction
    term:
      id: GO:0042310
      label: vasoconstriction
    modifier: INCREASED
  locations:
  - preferred_term: pulmonary artery
    term:
      id: UBERON:0002012
      label: pulmonary artery
  downstream:
  - target: Pulmonary Arterial Hypertension
    description: >-
      Elevated tone and vascular remodeling raise pulmonary artery pressure.
  - target: Exercise Intolerance
    description: >-
      Elevated pulmonary vascular tone contributes to reduced exercise capacity.
  evidence:
  - reference: PMID:16768548
    reference_title: Mutation of von Hippel-Lindau tumour suppressor and human cardiopulmonary physiology.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Basal ventilation and pulmonary vascular tone were elevated, and ventilatory, pulmonary vasoconstrictive, and heart rate responses to acute hypoxia were greatly increased."
    explanation: >-
      Direct physiological measurement of elevated basal pulmonary vascular tone
      and exaggerated hypoxic vasoconstriction in patients.
  - reference: PMID:16769575
    reference_title: "Endothelin-1, vascular endothelial growth factor and systolic pulmonary artery pressure in patients with Chuvash polycythemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Plasma endothelin-1 (p=0.010), VEGF (p=0.022) and erythropoietin (p<0.0005) concentrations and Doppler-estimated systolic pulmonary artery pressures (p<0.0005) were higher in the patients while systolic systemic blood pressures were lower (p=0.001)."
    explanation: >-
      Links elevated endothelin-1, a HIF target, to raised pulmonary artery
      pressure in patients.
  - reference: PMID:20197624
    reference_title: The von Hippel-Lindau Chuvash mutation promotes pulmonary hypertension and fibrosis in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "These mice developed pulmonary hypertension independently of polycythemia and enhanced normoxic respiration similar to Chuvash patients, further validating VhlR/R mice as a model for Chuvash disease."
    explanation: >-
      Establishes that the pulmonary phenotype is not secondary to the
      polycythemia, which is what justifies modeling it as a parallel branch.
  - reference: PMID:20197624
    reference_title: The von Hippel-Lindau Chuvash mutation promotes pulmonary hypertension and fibrosis in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Lungs from VhlR/R mice exhibited pulmonary vascular remodeling, hemorrhage, edema, and macrophage infiltration, and lungs from older mice also exhibited fibrosis."
    explanation: >-
      Documents the vascular remodeling that grounds conformance to the pulmonary
      vascular remodeling module.
- name: Hepcidin Suppression and Iron Mobilization
  biological_scale: ORGANISM
  description: >-
    Hepcidin, the master regulator of iron export, is suppressed roughly
    threefold in homozygotes, and the suppression survives adjustment for both
    erythropoietin and ferritin, so it is a direct consequence of the raised
    hypoxic response rather than a downstream effect of accelerated
    erythropoiesis. Transferrin and transferrin receptor are induced as HIF
    targets. The clinically important interaction is iatrogenic: therapeutic
    phlebotomy drives iron deficiency on top of this program, and lower ferritin
    independently predicts higher pulmonary artery pressure.
  downstream:
  - target: Decreased Circulating Ferritin Concentration
    description: >-
      HIF-driven iron mobilization compounded by therapeutic phlebotomy lowers
      ferritin.
  - target: Pulmonary Vascular Tone and Remodeling
    description: >-
      Lower ferritin independently predicts higher tricuspid regurgitation
      velocity, so iron depletion feeds back onto the pulmonary vascular node.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:21876117
    reference_title: Chuvash polycythemia VHLR200W mutation is associated with down-regulation of hepcidin expression.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "After adjustment for serum erythropoietin and ferritin concentrations by multiple linear regression, the geometric mean (95% confidence interval of mean) hepcidin concentration was 8.1 (6.3-10.5) ng/mL in VHL(R200W) homozygotes versus 26.9 (18.6-38.0) ng/mL in controls (P < .001)."
    explanation: >-
      Quantifies hepcidin suppression after adjustment for erythropoietin and
      ferritin, establishing it as a direct consequence of the hypoxic response.
  - reference: PMID:21993671
    reference_title: Pulmonary artery pressure and iron deficiency in patients with upregulation of hypoxia sensing due to homozygous VHL(R200W) mutation (Chuvash polycythemia).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Among VHL(R200W) homozygotes, phlebotomy therapy was associated with lower serum ferritin concentration, and low ferritin independently predicted higher tricuspid regurgitation velocity (standardized beta=0.29; P=0.009)."
    explanation: >-
      Establishes the iron-to-pulmonary-pressure link and its iatrogenic driver.
- name: Metabolic Reprogramming Toward Glycolysis
  biological_scale: CELLULAR
  description: >-
    Raised HIF activity induces glycolytic enzymes and pyruvate dehydrogenase
    kinase, shifting substrate use away from oxidative phosphorylation. During
    exercise this shows up as early phosphocreatine depletion and acidosis in
    skeletal muscle, greater blood lactate accumulation, and reduced maximum
    exercise capacity, with elevated muscle transcripts for pyruvate
    dehydrogenase kinase, phosphofructokinase, and muscle pyruvate kinase. This is
    the physiological substrate of the fatigue and exercise limitation patients
    report, and it is a rare opportunity to observe HIF-driven metabolic
    regulation at whole-organism level in humans.
  biological_processes:
  - preferred_term: glycolytic process
    term:
      id: GO:0006096
      label: glycolytic process
    modifier: INCREASED
  downstream:
  - target: Exercise Intolerance
    description: >-
      Early muscle acidosis and phosphocreatine depletion reduce maximum exercise
      capacity.
  - target: Fatigue
    description: >-
      The metabolic shift contributes to the chronic fatigue reported by patients.
  evidence:
  - reference: PMID:20616028
    reference_title: Regulation of human metabolism by hypoxia-inducible factor.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "During exercise, CP patients had early and marked phosphocreatine depletion and acidosis in skeletal muscle, greater accumulation of lactate in blood, and reduced maximum exercise capacities."
    explanation: >-
      Documents the metabolic phenotype during exercise in patients.
  - reference: PMID:20616028
    reference_title: Regulation of human metabolism by hypoxia-inducible factor.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Muscle biopsy specimens from CP patients showed elevated levels of transcript for pyruvate dehydrogenase kinase, phosphofructokinase, and muscle pyruvate kinase."
    explanation: >-
      Provides the transcriptional basis for the glycolytic shift in patient
      muscle.
- name: Increased Solid Organ Size
  biological_scale: TISSUE
  description: >-
    Liver, spleen, and kidney volumes relative to body mass are larger in
    homozygotes than in matched Chuvash controls. The proposed mechanism runs
    through the opposing effects of the two HIF isoforms on proliferation:
    HIF-1-alpha induces the cyclin-dependent kinase inhibitor p21, while
    HIF-2-alpha promotes MYC activity and proliferation, and mouse data implicate
    raised hepatic HIF-2-alpha with reduced p21.
  locations:
  - preferred_term: spleen
    term:
      id: UBERON:0002106
      label: spleen
  downstream:
  - target: Splenomegaly
    description: Splenic volume is increased relative to body mass.
  evidence:
  - reference: PMID:20140661
    reference_title: Increased size of solid organs in patients with Chuvash polycythemia and in mice with altered expression of HIF-1alpha and HIF-2alpha.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Here we report that the volumes of liver, spleen, and kidneys relative to body mass were larger in 30 individuals with Chuvash polycythemia than in 30 matched Chuvash controls."
    explanation: >-
      Documents the organ enlargement in a matched human cohort.
  - reference: PMID:20140661
    reference_title: Increased size of solid organs in patients with Chuvash polycythemia and in mice with altered expression of HIF-1alpha and HIF-2alpha.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "At least in the liver, this phenotype may result from increased HIF-2alpha and decreased p21(Cip1) levels leading to increased hepatocyte proliferation."
    explanation: >-
      Offers the proposed HIF-2-alpha and p21 mechanism. PARTIAL because the
      authors themselves frame it as a hypothesis supported by mouse data.
mechanistic_hypotheses:
- hypothesis_group_id: canonical_hif_stabilization
  hypothesis_label: Impaired pVHL-HIF Degradation with Normoxic HIF Stabilization
  status: CANONICAL
  description: >-
    The established account. R200W weakens pVHL binding to hydroxylated HIF-alpha,
    HIF-1-alpha and HIF-2-alpha escape proteasomal degradation at normal oxygen
    tension, and the hypoxia-response transcriptional program runs constitutively,
    producing erythropoietin excess, pulmonary vascular changes, altered iron
    handling, and metabolic reprogramming. Mouse epistasis assigns the erythroid
    and pulmonary arms specifically to HIF-2-alpha.
  evidence:
  - reference: PMID:12415268
    reference_title: Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The protein VHL modulates the ubiquitination and subsequent destruction of hypoxia-inducible factor 1, subunit alpha (HIF1alpha)."
    explanation: >-
      States the normal pVHL function whose impairment is the basis of this model.
- hypothesis_group_id: vhl_socs1_jak2_dysregulation
  hypothesis_label: Loss of VHL-SOCS1-Mediated Degradation of Phospho-JAK2
  status: ALTERNATIVE
  description: >-
    A competing account of why erythroid progenitors are hypersensitive to
    erythropoietin. pVHL is proposed to heterodimerize with SOCS1 to form an E3
    ligase that degrades phosphorylated JAK2, and Chuvash-associated VHL mutants
    are proposed to have altered SOCS1 affinity and to fail to degrade
    phospho-JAK2, so erythropoietin signaling runs hot independently of HIF. A
    selective JAK2 inhibitor reversed the phenotype in the knock-in mouse. Human
    data cut against it: the Croatian H191D genotype, which the model treats the
    same way, has erythroid progenitors that are explicitly not hypersensitive to
    erythropoietin. Recorded as an alternative rather than dismissed, because the
    mouse rescue is real and the isolated human report of clinical improvement on
    a JAK2 inhibitor is consistent with it, though JAK2 inhibition would blunt
    erythropoietin signaling regardless of why that signaling is high.
  evidence:
  - reference: PMID:21685897
    reference_title: Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Here we show that VHL directly binds suppressor of cytokine signaling 1 (SOCS1) to form a heterodimeric E3 ligase that targets phosphorylated JAK2 (pJAK2) for ubiquitin-mediated destruction."
    explanation: >-
      States the proposed alternative E3 ligase mechanism.
  - reference: PMID:21685897
    reference_title: Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Systemic administration of a highly selective JAK2 inhibitor, TG101209, reversed the disease phenotype in Vhl(R200W/R200W) knock-in mice, an experimental model that recapitulates human Chuvash polycythemia."
    explanation: >-
      The mouse rescue that is the strongest support for this alternative model.
  - reference: PMID:23403324
    reference_title: "The phenotype of polycythemia due to Croatian homozygous VHL (571C>G:H191D) mutation is different from that of Chuvash polycythemia (VHL 598C>T:R200W)."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "This observation contrasts with a report suggesting that polycythemia in VHL R200W and H191D homozygotes is due to the loss of JAK2 regulation from VHL R200W and H191D binding to SOCS1."
    explanation: >-
      Human progenitor data contradicting the model's prediction for H191D, which
      is why it is curated as ALTERNATIVE rather than canonical.
phenotypes:
- name: Increased Circulating Hemoglobin Concentration
  category: Hematologic
  description: >-
    Markedly elevated hemoglobin present from birth or infancy, with a mean of
    22.6 g/dL in six young Chuvash patients.
  phenotype_term:
    preferred_term: Increased circulating hemoglobin concentration
    term:
      id: HP:0001900
      label: Increased circulating hemoglobin concentration
  diagnostic: true
  evidence:
  - reference: PMID:9058738
    reference_title: Congenital polycythemia in Chuvashia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hemoglobins were markedly elevated in the index subjects"
    explanation: >-
      Documents marked hemoglobin elevation in affected subjects under 20 years
      old. The reported mean of 22.6 g/dL immediately follows in the abstract but
      is bracketed by an abbreviation the snippet validator strips, so the quote
      stops short of it.
- name: Increased Hematocrit
  category: Hematologic
  description: >-
    Elevated hematocrit is the presenting laboratory abnormality and the reason
    most patients come to attention. It is notably not the driver of the
    thrombotic risk.
  phenotype_term:
    preferred_term: Increased hematocrit
    term:
      id: HP:0001899
      label: Increased hematocrit
  diagnostic: true
  evidence:
  - reference: PMID:37435906
    reference_title: Increased transferrin protects from thrombosis in Chuvash erythrocytosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Homozygous VHLR200W results in accumulation of HIFs that increase transcription of the erythropoietin gene and raise hematocrit."
    explanation: >-
      States the mechanistic route from the genotype to the raised hematocrit.
- name: Elevated Circulating Erythropoietin Concentration
  category: Hematologic
  description: >-
    Erythropoietin is inappropriately high for the hemoglobin, about tenfold
    higher than matched controls after adjustment, though it can fall within the
    normal laboratory range in individual patients. A normal erythropoietin does
    not exclude the diagnosis. This is also the prognostic variable that tracks
    thrombotic risk.
  phenotype_term:
    preferred_term: Elevated circulating erythropoietin concentration
    term:
      id: HP:0033644
      label: Elevated circulating erythropoietin concentration
  diagnostic: true
  evidence:
  - reference: PMID:14726398
    reference_title: "Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Although hemoglobin-adjusted serum erythropoietin concentrations were approximately 10-fold higher in VHL 598C>T homozygotes than in controls, erythropoietin response to hypoxia was identical."
    explanation: >-
      Quantifies the erythropoietin elevation against matched controls.
- name: Arterial Thrombosis
  category: Vascular
  description: >-
    Arterial thrombotic events are part of the vascular complication burden that
    dominates outcome. Risk is driven by erythropoietin elevation rather than by
    hematocrit.
  phenotype_term:
    preferred_term: Arterial thrombosis
    term:
      id: HP:0004420
      label: Arterial thrombosis
  evidence:
  - reference: PMID:16673284
    reference_title: Vascular complications in Chuvash polycythemia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These studies have also shown associations with arterial and venous thrombosis, major bleeding episodes, cerebral vascular events, and premature mortality."
    explanation: >-
      Documents arterial thrombosis among the vascular complications established
      by matched-cohort and case-control analysis.
- name: Venous Thrombosis
  category: Vascular
  description: >-
    Venous thrombotic events, including deep vein thrombosis, occur alongside the
    arterial events. Over eleven years of prospective follow-up thrombotic risk
    was 8.9-fold higher in patients than matched controls.
  phenotype_term:
    preferred_term: Venous thrombosis
    term:
      id: HP:0004936
      label: Venous thrombosis
  evidence:
  - reference: PMID:16673284
    reference_title: Vascular complications in Chuvash polycythemia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These studies have also shown associations with arterial and venous thrombosis, major bleeding episodes, cerebral vascular events, and premature mortality."
    explanation: >-
      Documents venous thrombosis among the established vascular complications.
  - reference: PMID:37435906
    reference_title: Increased transferrin protects from thrombosis in Chuvash erythrocytosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "During 11 years of follow-up, risk of thrombosis increased 8.9-fold in patients versus controls."
    explanation: >-
      Quantifies the prospective thrombotic risk against matched controls.
- name: Stroke
  category: Neurologic
  description: >-
    Cerebral vascular events are the leading identified contributor to premature
    mortality in this disease.
  phenotype_term:
    preferred_term: Stroke
    term:
      id: HP:0001297
      label: Stroke
  evidence:
  - reference: PMID:14726398
    reference_title: "Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In this matched cohort study, VHL 598C>T homozygosity was associated with vertebral hemangiomas, varicose veins, lower blood pressures, and elevated serum vascular endothelial growth factor (VEGF) concentrations (P <.0005), as well as premature mortality related to cerebral vascular events and peripheral thrombosis."
    explanation: >-
      Links cerebral vascular events to premature mortality in the matched cohort.
- name: Pulmonary Arterial Hypertension
  category: Cardiovascular
  description: >-
    Mild pulmonary hypertension was present in 5 of 14 patients (36%) and no
    controls by Doppler echocardiography, and tricuspid regurgitation velocity
    remains elevated after adjustment for blood-volume surrogates.
  phenotype_term:
    preferred_term: Pulmonary arterial hypertension
    term:
      id: HP:0002092
      label: Pulmonary arterial hypertension
  frequency: FREQUENT
  evidence:
  - reference: PMID:16769575
    reference_title: "Endothelin-1, vascular endothelial growth factor and systolic pulmonary artery pressure in patients with Chuvash polycythemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Five (36%) patients and no controls had mild pulmonary hypertension defined as systolic pulmonary artery pressure (c) 35 mmHg."
    explanation: >-
      36% of 14 patients versus none of 14 controls, within the FREQUENT band of
      30 to 79%.
  - reference: PMID:21993671
    reference_title: Pulmonary artery pressure and iron deficiency in patients with upregulation of hypoxia sensing due to homozygous VHL(R200W) mutation (Chuvash polycythemia).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The age-adjusted mean ± SE tricuspid regurgitation velocity was higher in VHL(R200W) homozygotes than controls with normal VHL alleles (2.5±0.03 vs. 2.3±0.05 m/sec, P=0.005)."
    explanation: >-
      Confirms elevated estimated pulmonary artery pressure in a larger cohort of
      120 homozygotes.
- name: Varicose Veins
  category: Vascular
  description: >-
    Varicose veins were among the vascular abnormalities significantly associated
    with the genotype in the matched cohort study.
  phenotype_term:
    preferred_term: Varicose veins
    term:
      id: HP:0002619
      label: Varicose veins
  evidence:
  - reference: PMID:14726398
    reference_title: "Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In this matched cohort study, VHL 598C>T homozygosity was associated with vertebral hemangiomas, varicose veins, lower blood pressures, and elevated serum vascular endothelial growth factor (VEGF) concentrations (P <.0005), as well as premature mortality related to cerebral vascular events and peripheral thrombosis."
    explanation: >-
      Lists varicose veins among the genotype-associated vascular abnormalities.
- name: Hemangioma
  category: Vascular
  description: >-
    Vertebral hemangiomas are associated with the genotype. Note these are benign
    vascular malformations, and they are emphatically not the spinocerebellar
    hemangioblastomas of classical von Hippel-Lindau syndrome, which are absent in
    this disease.
  phenotype_term:
    preferred_term: Vertebral hemangioma
    term:
      id: HP:0001028
      label: Hemangioma
  evidence:
  - reference: PMID:14726398
    reference_title: "Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In this matched cohort study, VHL 598C>T homozygosity was associated with vertebral hemangiomas, varicose veins, lower blood pressures, and elevated serum vascular endothelial growth factor (VEGF) concentrations (P <.0005), as well as premature mortality related to cerebral vascular events and peripheral thrombosis."
    explanation: >-
      Documents vertebral hemangiomas as a genotype-associated finding.
- name: Low-To-Normal Blood Pressure
  category: Cardiovascular
  description: >-
    Systemic blood pressures are lower than in matched controls, an unusual
    counterpoint sitting inside an otherwise prothrombotic phenotype.
  phenotype_term:
    preferred_term: Low-to-normal blood pressure
    term:
      id: HP:0002632
      label: Low-to-normal blood pressure
  evidence:
  - reference: PMID:16769575
    reference_title: "Endothelin-1, vascular endothelial growth factor and systolic pulmonary artery pressure in patients with Chuvash polycythemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Plasma endothelin-1 (p=0.010), VEGF (p=0.022) and erythropoietin (p<0.0005) concentrations and Doppler-estimated systolic pulmonary artery pressures (p<0.0005) were higher in the patients while systolic systemic blood pressures were lower (p=0.001)."
    explanation: >-
      Reports significantly lower systolic systemic blood pressures in patients.
- name: Exercise Intolerance
  category: Constitutional
  description: >-
    Reduced maximum exercise capacity with early muscle acidosis and
    phosphocreatine depletion, the objective correlate of the fatigue patients
    describe.
  phenotype_term:
    preferred_term: Exercise intolerance
    term:
      id: HP:0003546
      label: Exercise intolerance
  evidence:
  - reference: PMID:20616028
    reference_title: Regulation of human metabolism by hypoxia-inducible factor.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "During exercise, CP patients had early and marked phosphocreatine depletion and acidosis in skeletal muscle, greater accumulation of lactate in blood, and reduced maximum exercise capacities."
    explanation: >-
      Directly measures reduced maximum exercise capacity with its metabolic
      correlates.
- name: Headache
  category: Neurologic
  description: >-
    Chronic headache is among the commonest symptoms reported by patients,
    attributed to hyperviscosity.
  phenotype_term:
    preferred_term: Headache
    term:
      id: HP:0002315
      label: Headache
    temporality: CHRONIC
  evidence:
  - reference: PMID:37435906
    reference_title: Increased transferrin protects from thrombosis in Chuvash erythrocytosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Phlebotomies reduce hematocrit and hyperviscosity symptoms."
    explanation: >-
      Establishes hyperviscosity symptoms as a treated feature of the disease.
      PARTIAL because headache is not named individually in this source.
- name: Fatigue
  category: Constitutional
  description: >-
    Chronic fatigue is a persistent symptom, with both hyperviscosity and the
    glycolytic metabolic shift plausibly contributing.
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
    temporality: CHRONIC
  evidence:
  - reference: PMID:20616028
    reference_title: Regulation of human metabolism by hypoxia-inducible factor.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "During exercise, CP patients had early and marked phosphocreatine depletion and acidosis in skeletal muscle, greater accumulation of lactate in blood, and reduced maximum exercise capacities."
    explanation: >-
      Provides the objective metabolic substrate for exertional fatigue. PARTIAL
      because fatigue as a reported symptom is not itself measured here.
- name: Splenomegaly
  category: Hematologic
  description: >-
    Splenic volume relative to body mass is increased compared with matched
    controls, alongside liver and kidney.
  phenotype_term:
    preferred_term: Splenomegaly
    term:
      id: HP:0001744
      label: Splenomegaly
  evidence:
  - reference: PMID:20140661
    reference_title: Increased size of solid organs in patients with Chuvash polycythemia and in mice with altered expression of HIF-1alpha and HIF-2alpha.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Here we report that the volumes of liver, spleen, and kidneys relative to body mass were larger in 30 individuals with Chuvash polycythemia than in 30 matched Chuvash controls."
    explanation: >-
      Documents increased splenic volume in a matched cohort of 30 patients.
- name: Decreased Circulating Ferritin Concentration
  category: Hematologic
  description: >-
    Ferritin is reduced, driven both by HIF-mediated iron mobilization and, more
    consequentially, by therapeutic phlebotomy. Low ferritin independently
    predicts higher pulmonary artery pressure, which makes this a treatment-caused
    phenotype worth modeling rather than a passive laboratory finding.
  phenotype_term:
    preferred_term: Decreased circulating ferritin concentration
    term:
      id: HP:0012343
      label: Decreased circulating ferritin concentration
  evidence:
  - reference: PMID:37435906
    reference_title: Increased transferrin protects from thrombosis in Chuvash erythrocytosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Baseline transferrin was elevated, and ferritin reduced in patients."
    explanation: >-
      Documents reduced ferritin with elevated transferrin at steady state.
  - reference: PMID:21993671
    reference_title: Pulmonary artery pressure and iron deficiency in patients with upregulation of hypoxia sensing due to homozygous VHL(R200W) mutation (Chuvash polycythemia).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Among VHL(R200W) homozygotes, phlebotomy therapy was associated with lower serum ferritin concentration, and low ferritin independently predicted higher tricuspid regurgitation velocity (standardized beta=0.29; P=0.009)."
    explanation: >-
      Attributes the ferritin fall to phlebotomy and links it to raised pulmonary
      artery pressure.
biochemical:
- name: Suppressed Serum Hepcidin
  presence: DECREASED
  context: >-
    Serum hepcidin is about threefold lower in homozygotes than controls after
    adjustment for erythropoietin and ferritin, and no independent relationship
    of erythropoietin, hemoglobin, or red cell count with hepcidin was found. That
    adjustment is the point: hepcidin suppression here is a direct consequence of
    the raised hypoxic response rather than a downstream effect of accelerated
    erythropoiesis, which is a genuinely informative dissociation for iron
    biology generally.
  evidence:
  - reference: PMID:21876117
    reference_title: Chuvash polycythemia VHLR200W mutation is associated with down-regulation of hepcidin expression.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In contrast, a significant independent relationship of serum erythropoietin, hemoglobin, or RBC count with hepcidin was not observed."
    explanation: >-
      Establishes that the hepcidin suppression is independent of erythropoietin
      and red cell mass.
- name: Elevated Serum Transferrin
  presence: INCREASED
  context: >-
    Transferrin is elevated as a HIF target and further raised by iron deficiency.
    The clinically surprising part is its direction of association: transferrin
    elevation was associated with reduced rather than increased thrombosis risk,
    and the A allele of the intronic TF variant rs3811647 associated with higher
    transferrin and protection from thrombosis. The investigators say plainly that
    they did not expect this.
  evidence:
  - reference: PMID:37435906
    reference_title: Increased transferrin protects from thrombosis in Chuvash erythrocytosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Unexpectedly, transferrin elevation associated with reduced rather than increased thrombosis risk."
    explanation: >-
      The protective direction of the transferrin association, stated by the
      authors as unexpected.
  - reference: PMID:37435906
    reference_title: Increased transferrin protects from thrombosis in Chuvash erythrocytosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The A allele of the promoter EPO single nucleotide polymorphisms (SNP), rs1617640, associated with elevated erythropoietin and increased thrombosis risk, whereas the A allele of the intronic TF SNP, rs3811647, associated with higher transferrin and protection from thrombosis in patients."
    explanation: >-
      Provides the genetic modifier evidence supporting both the risk and
      protective directions.
genetic:
- name: VHL c.598C>T (p.Arg200Trp) Homozygosity
  gene_term:
    preferred_term: VHL
    term:
      id: hgnc:12687
      label: VHL
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  features: >-
    Homozygosity for the germline VHL missense allele c.598C>T, p.Arg200Trp
    (rs28940298), at chromosome 3p25. The functional consequence is partial loss
    of function: the substitution weakens rather than abolishes pVHL binding to
    hydroxylated HIF-alpha. That hypomorphic character is why this is a
    hypoxia-sensing disorder and not a tumor syndrome. Congenital erythrocytosis
    also arises from compound heterozygosity of R200W with a second VHL allele and
    from other homozygous VHL alleles such as the Croatian H191D, which is
    phenotypically distinct. Coding-exon-only assays can miss splice-altering
    variants including a cryptic intron-1 exon, so a negative coding panel does
    not exclude VHL-related erythrocytosis.
  frequency: OBLIGATE
  evidence:
  - reference: PMID:12415268
    reference_title: Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The gene associated with von Hippel-Lindau syndrome, VHL, maps to this region, and homozygosity with respect to a C-->T missense mutation in VHL, causing an arginine-to-tryptophan change at amino-acid residue 200 (Arg200Trp), was identified in all individuals affected with Chuvash polycythemia."
    explanation: >-
      Establishes homozygosity for VHL R200W in all affected individuals.
  - reference: PMID:16768548
    reference_title: Mutation of von Hippel-Lindau tumour suppressor and human cardiopulmonary physiology.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Chuvash polycythaemia has recently been defined as a new form of VHL-associated disease, distinct from the classical VHL-associated inherited cancer syndrome, in which germline homozygosity for a hypomorphic VHL allele causes a generalised abnormality in VHL-HIF signalling."
    explanation: >-
      States explicitly that the causative allele is hypomorphic, which is the
      basis for separating this disease from the VHL cancer syndrome.
- name: EPO Promoter Variant rs1617640
  gene_term:
    preferred_term: EPO
    term:
      id: hgnc:3415
      label: EPO
  relationship_type: MODIFIER
  variant_origin: GERMLINE
  features: >-
    The A allele of the erythropoietin promoter variant rs1617640 associates with
    elevated erythropoietin and increased thrombosis risk among VHL R200W
    homozygotes. This is the genetic mechanism sitting directly behind the
    entry's headline finding that erythropoietin, rather than hematocrit, is what
    predicts thrombosis.
  evidence:
  - reference: PMID:37435906
    reference_title: Increased transferrin protects from thrombosis in Chuvash erythrocytosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The A allele of the promoter EPO single nucleotide polymorphisms (SNP), rs1617640, associated with elevated erythropoietin and increased thrombosis risk, whereas the A allele of the intronic TF SNP, rs3811647, associated with higher transferrin and protection from thrombosis in patients."
    explanation: >-
      Establishes the risk-increasing direction of the EPO promoter variant in
      patients.
- name: TF Intronic Variant rs3811647
  gene_term:
    preferred_term: TF
    term:
      id: hgnc:11740
      label: TF
  relationship_type: MODIFIER
  variant_origin: GERMLINE
  features: >-
    The A allele of the transferrin intronic variant rs3811647 associates with
    higher transferrin and protection from thrombosis in patients. Together with
    the EPO promoter variant it forms the only well-documented pair of genetic
    modifiers in this disease, and the protective direction was explicitly
    unexpected to the investigators.
  evidence:
  - reference: PMID:37435906
    reference_title: Increased transferrin protects from thrombosis in Chuvash erythrocytosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The A allele of the promoter EPO single nucleotide polymorphisms (SNP), rs1617640, associated with elevated erythropoietin and increased thrombosis risk, whereas the A allele of the intronic TF SNP, rs3811647, associated with higher transferrin and protection from thrombosis in patients."
    explanation: >-
      Establishes the protective direction of the transferrin variant in patients.
inheritance:
- name: Autosomal Recessive
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >-
    Autosomal recessive. Heterozygotes are clinically unaffected but not
    biologically silent: they have increased HIF-1-alpha activity and appear to be
    protected from anemia, with the odds of anemia reduced about 5.6-fold compared
    with non-carriers. That heterozygote advantage is the leading explanation for
    why an allele that shortens homozygote life expectancy has persisted at 5.7%
    in Chuvashia and 7.0% on Ischia. The allele descends largely from a single
    ancient founder event, but not exclusively so, since at least one Turkish
    homozygote carries a distinct haplotype.
  evidence:
  - reference: PMID:21606165
    reference_title: The heterozygote advantage of the Chuvash polycythemia VHLR200W mutation may be protection against anemia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "By multivariate logistic regression, the odds of anemia were reduced an estimated 5.6-fold in the VHL(R200W) heterozygotes compared to controls (95% confidence interval 1.4-22.7; P=0.017)."
    explanation: >-
      Quantifies the proposed heterozygote advantage that would maintain the allele
      in the population.
  - reference: PMID:14726398
    reference_title: "Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Although endemic to the Chuvash population of Russia, this mutation occurs worldwide and originates from a single ancient event."
    explanation: >-
      Establishes the founder origin of the allele and its worldwide occurrence.
prevalence:
- population: Island of Ischia, Campania, Italy (allele frequency)
  measure_type: CARRIER_FREQUENCY
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 7000.0
  notes: >-
    Mutated allele frequency 0.070 on Ischia versus 0.057 in Chuvashia. Recorded
    here as an allele frequency, expressed per 100,000 alleles, not as a disease
    prevalence. Deriving a homozygote prevalence from these by Hardy-Weinberg
    would be arithmetic rather than a published figure and is deliberately not
    done.
  evidence:
  - reference: PMID:16210343
    reference_title: "Von Hippel-Lindau-dependent polycythemia is endemic on the island of Ischia: identification of a novel cluster."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "From analysis of the mutated allele, we found that the disease was more frequent on Ischia (0.070) than in Chuvashia (0.057)."
    explanation: >-
      Gives the mutated allele frequencies for both endemic clusters.
- population: Worldwide
  measure_type: POINT_PREVALENCE
  prevalence_class: UNKNOWN
  notes: >-
    Orphanet records the worldwide point prevalence for Chuvash erythrocytosis as
    unknown and not yet validated, and no published incidence figure was found. The
    disease is qualitatively described as affecting hundreds of individuals in
    Chuvashia and as the only endemic form of familial and congenital polycythemia
    described. Recording UNKNOWN rather than inventing a number.
  evidence:
  - reference: PMID:9058738
    reference_title: Congenital polycythemia in Chuvashia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hundreds of individuals appear to be affected in an autosomal recessive pattern."
    explanation: >-
      A qualitative statement of case load in the endemic region. PARTIAL because
      it supports no numeric prevalence estimate.
progression:
- phase: Congenital and childhood
  notes: >-
    Erythrocytosis is present from birth or infancy and is often documented in
    childhood; the six index subjects in the original Chuvash series were all
    under 20 years old. Onset is insidious rather than acute, and there is no
    presenting event.
  evidence:
  - reference: PMID:9058738
    reference_title: Congenital polycythemia in Chuvashia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We studied six polycythemic Chuvash patients <20 years of age from unrelated families and 12 first-degree family members."
    explanation: >-
      Establishes that the phenotype is present and detectable in childhood and
      adolescence.
- phase: Adult event-driven course
  notes: >-
    Hematologically the disease is stable or slowly progressive; clinically it is
    event-driven, punctuated by discrete thrombotic and cerebrovascular events
    that accumulate with age and produce premature mortality. Pulmonary artery
    pressure is a progressive variable that is modifiable by iron status.
  evidence:
  - reference: PMID:14726398
    reference_title: "Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In this matched cohort study, VHL 598C>T homozygosity was associated with vertebral hemangiomas, varicose veins, lower blood pressures, and elevated serum vascular endothelial growth factor (VEGF) concentrations (P <.0005), as well as premature mortality related to cerebral vascular events and peripheral thrombosis."
    explanation: >-
      Establishes the event-driven vascular course and its contribution to
      premature mortality.
clinical_burden:
  burden_level: HIGH
  rationale: >-
    Thrombosis and cerebrovascular events drive premature mortality, with an
    8.9-fold increase in thrombotic risk over eleven years of prospective
    follow-up against matched controls. Chronic headache, fatigue, and reduced
    exercise capacity persist between events, and about a third of patients carry
    mild pulmonary hypertension. Notably absent is any excess cancer risk, despite
    the causative gene being a tumor suppressor. There is no therapy of
    demonstrated benefit, and the standard of care, phlebotomy, is itself
    associated with increased thrombotic risk and with higher pulmonary artery
    pressure through iron depletion.
  evidence:
  - reference: PMID:37435906
    reference_title: Increased transferrin protects from thrombosis in Chuvash erythrocytosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "However, the major cause of morbidity and mortality in Chuvash erythrocytosis is thrombosis."
    explanation: >-
      Identifies thrombosis as the dominant source of morbidity and mortality.
  - reference: PMID:16673284
    reference_title: Vascular complications in Chuvash polycythemia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Spinocerebellar hemangioblastomas, renal carcinomas, and pheochromocytomas typical of classical VHL tumor predisposition syndrome have not been found, and no increased risk of cancer has been demonstrated."
    explanation: >-
      Establishes the absence of demonstrated excess cancer risk, which materially
      changes the burden profile relative to classical VHL syndrome.
diagnosis:
- name: Diagnostic Workup for Congenital Erythrocytosis
  description: >-
    Confirm persistent erythrocytosis, then exclude polycythemia vera (JAK2
    unmutated; and note that white cell and platelet counts are normal or low here
    rather than expanded), exclude acquired secondary causes such as
    cardiopulmonary disease, high-altitude residence, sleep apnea, renal artery
    stenosis, and erythropoiesis-stimulating agents, then measure erythropoietin
    (high or inappropriately normal, and a normal value does not exclude the
    diagnosis) and p50 (normal here, left-shifted in high-affinity
    hemoglobinopathies), then confirm genetically.
  evidence:
  - reference: PMID:34021251
    reference_title: "JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Workup for hereditary/congenital erythrocytosis requires documentation of family history and laboratory screening for high-oxygen affinity hemoglobin variants, 2, 3 biphosphoglycerate deficiency, and germline mutations that are known to alter cellular oxygen sensing (e.g., PHD2, HIF2A, VHL) or EPO signaling (e.g., EPOR mutations); the latter is uniquely associated with subnormal EPO."
    explanation: >-
      Sets out the diagnostic algorithm for congenital erythrocytosis including
      the VHL oxygen-sensing route.
  - reference: PMID:9058738
    reference_title: Congenital polycythemia in Chuvashia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Familial and congenital polycythemia, not due to high oxygen affinity hemoglobin or reduced 2,3-diphosphoglycerate in erythrocytes, is common in the Chuvash population of the Russian Federation."
    explanation: >-
      Establishes normal oxygen affinity and normal 2,3-diphosphoglycerate as part
      of the diagnostic signature.
- name: VHL Genetic Testing
  description: >-
    Targeted single-variant testing for VHL c.598C>T is efficient where the allele
    is common; otherwise a congenital erythrocytosis gene panel covering VHL,
    EPAS1, EGLN1, EPOR, the globin genes, and BPGM, escalating to exome or genome
    sequencing. A coding-exon-only assay can miss splice-altering variants
    including those in a cryptic intron-1 exon, so a clean coding VHL result in a
    high-suspicion case is a reason to look further rather than to stop.
  evidence:
  - reference: PMID:37362405
    reference_title: "A Screening Approach for Inherited Erythrocytosis due to the VHL:c.598C > T Mutation (Chuvash Polycythemia)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Despite a lower frequency (8%) compared to literature, our results suggest that the relatively simpler PCR-RFLP for VHL:c.598C > T mutation may be considered for the initial genetic screening of unexplained, suspected congenital erythrocytosis in regions where Chuvash polycythemia comprises a large proportion of inherited erythrocytosis, after polycythemia vera and common acquired secondary causes are excluded."
    explanation: >-
      Supports targeted single-variant PCR-RFLP as a first-line genetic screen
      where the allele is common, and states the prerequisite exclusions.
  - reference: PMID:29891534
    reference_title: Identification of a new VHL exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Here, we identify a new VHL cryptic exon (termed E1') deep in intron 1 that is naturally expressed in many tissues."
    explanation: >-
      Identifies the intron-1 cryptic exon that a coding-exon-only assay cannot
      see.
  - reference: PMID:29891534
    reference_title: Identification of a new VHL exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In addition, we demonstrate a pathogenic role for synonymous mutations in VHL exon 2 that altered splicing through E2-skipping in 5 families with erythrocytosis or VHL disease."
    explanation: >-
      Establishes that synonymous coding variants can be pathogenic through
      splicing, so a clean coding readout does not exclude the diagnosis.
  - reference: PMID:34021251
    reference_title: "JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Workup for hereditary/congenital erythrocytosis requires documentation of family history and laboratory screening for high-oxygen affinity hemoglobin variants, 2, 3 biphosphoglycerate deficiency, and germline mutations that are known to alter cellular oxygen sensing (e.g., PHD2, HIF2A, VHL) or EPO signaling (e.g., EPOR mutations); the latter is uniquely associated with subnormal EPO."
    explanation: >-
      Supports the panel composition for congenital erythrocytosis genetic
      testing.
- name: Echocardiographic Screening for Pulmonary Hypertension
  description: >-
    Doppler echocardiography with tricuspid regurgitation velocity, interpreted
    with the caveat that this measure is influenced by blood volume and iron
    status. In the largest cohort the elevation persisted after adjustment for
    left ventricular diastolic and left atrial diameters, so it is not merely a
    volume artifact.
  evidence:
  - reference: PMID:21993671
    reference_title: Pulmonary artery pressure and iron deficiency in patients with upregulation of hypoxia sensing due to homozygous VHL(R200W) mutation (Chuvash polycythemia).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The age-adjusted left ventricular diastolic diameter (4.8±0.05 vs. 4.5±0.09 cm, P=0.005) and left atrial diameter (3.4±0.04 vs. 3.2±0.08 cm, P=0.011) were also greater in the VHL(R200W) homozygotes, consistent with increased blood volume, but the elevation in tricuspid regurgitation velocity persisted after adjustment for these variables."
    explanation: >-
      Documents both the confound and the adjustment that survives it.
treatments:
- name: Therapeutic Phlebotomy
  description: >-
    The contested standard of care. Phlebotomy reliably reduces hematocrit and
    relieves hyperviscosity symptoms, and that is the whole of its demonstrated
    benefit. Against it: it causes iron deficiency, low ferritin independently
    predicts higher pulmonary artery pressure, and thrombotic risk is
    paradoxically increased by phlebotomy in this disease. Current expert opinion
    is that cytoreductive therapy should be avoided and phlebotomy is seldom
    warranted, with frequency set by symptom control rather than a hematocrit
    threshold. This is the rare treatment whose target node and harm node are
    different nodes, and the entry models it that way.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: phlebotomy
    term:
      id: NCIT:C28221
      label: Phlebotomy
  target_mechanisms:
  - target: Erythropoietin Excess and Erythroid Expansion
    treatment_effect: INHIBITS
    description: >-
      Phlebotomy removes red cell mass, lowering hematocrit and relieving
      hyperviscosity symptoms. It acts on the erythroid output, not on the
      prothrombotic node that determines outcome.
  evidence:
  - reference: PMID:37435906
    reference_title: Increased transferrin protects from thrombosis in Chuvash erythrocytosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Phlebotomies reduce hematocrit and hyperviscosity symptoms."
    explanation: >-
      States the demonstrated benefit of phlebotomy, which is symptomatic.
  - reference: PMID:30872370
    reference_title: Re-evaluation of hematocrit as a determinant of thrombotic risk in erythrocytosis.
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "We review studies indicating that the occurrence of thrombosis in Chuvash erythrocytosis is independent of hematocrit, that the thrombotic risk is paradoxically increased by phlebotomy in Chuvash erythrocytosis, and that, when compared to chemotherapy, phlebotomy is associated with increased thrombotic risk in polycythemia vera."
    explanation: >-
      Refutes the thrombosis-prevention rationale for phlebotomy and reports the
      opposite association.
  - reference: PMID:21993671
    reference_title: Pulmonary artery pressure and iron deficiency in patients with upregulation of hypoxia sensing due to homozygous VHL(R200W) mutation (Chuvash polycythemia).
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "Among VHL(R200W) homozygotes, phlebotomy therapy was associated with lower serum ferritin concentration, and low ferritin independently predicted higher tricuspid regurgitation velocity (standardized beta=0.29; P=0.009)."
    explanation: >-
      Documents the second harm route, phlebotomy-induced iron deficiency raising
      estimated pulmonary artery pressure.
  - reference: PMID:34021251
    reference_title: "JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In general, cytoreductive therapy should be avoided and phlebotomy is seldom warranted where frequency is determined by symptom control rather than Hct threshold."
    explanation: >-
      Current expert position on how, and how little, to use phlebotomy here.
- name: Low-Dose Aspirin
  description: >-
    Widely advised on general cardiovascular grounds, and not demonstrated to
    benefit this disease specifically. Retrospective analyses have not shown
    benefit for either phlebotomy or aspirin, and the authors of those analyses
    call for prospective study.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: acetylsalicylic acid
      term:
        id: CHEBI:15365
        label: acetylsalicylic acid
  evidence:
  - reference: PMID:16673284
    reference_title: Vascular complications in Chuvash polycythemia.
    supports: NO_EVIDENCE
    evidence_source: HUMAN_CLINICAL
    snippet: "Retrospective analyses among patients with Chuvash polycythemia have not shown benefit for therapy with phlebotomy or aspirin, but these and other modes of therapy should be studied prospectively."
    explanation: >-
      Reports the absence of demonstrated benefit for aspirin in retrospective
      analysis, without establishing harm.
  - reference: PMID:34021251
    reference_title: "JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Although not supported by hard evidence, cardiovascular risk optimization and low-dose aspirin use are often advised."
    explanation: >-
      Records that aspirin is commonly advised while stating that hard evidence is
      lacking, which is exactly the epistemic status this entry assigns it.
- name: Anticoagulation for Documented Thrombosis
  description: >-
    Anticoagulation is used for treatment and secondary prevention of documented
    thrombotic events, following general thrombosis practice rather than any
    disease-specific evidence. There is no controlled evidence on primary
    thromboprophylaxis in this disease, which is a conspicuous gap given that
    thrombosis is what kills people.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: anticoagulation therapy
    term:
      id: NCIT:C63341
      label: Anticoagulation Therapy
  evidence:
  - reference: PMID:16673284
    reference_title: Vascular complications in Chuvash polycythemia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These studies have also shown associations with arterial and venous thrombosis, major bleeding episodes, cerebral vascular events, and premature mortality."
    explanation: >-
      Establishes the thrombotic burden that motivates anticoagulation. PARTIAL
      because it also documents major bleeding episodes, so the risk-benefit
      balance is not settled, and no anticoagulation trial exists in this disease.
- name: HIF-2-alpha Inhibition
  description: >-
    The mechanism-matched therapy, and the most interesting open question in the
    disease. The second-generation allosteric HIF-2-alpha inhibitor belzutifan
    decreased erythropoietin production and reversed polycythemia in three
    relevant mouse models, and also lowered right ventricular pressure and
    mitigated pulmonary hypertension to near wild-type levels. The evidence is
    preclinical. There is a published human case of response in congenital
    polycythemia, but it is a single compound heterozygote rather than an R200W
    homozygote, and the cached record for that report carries no abstract text, so
    it is recorded in notes rather than cited as evidence here.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: belzutifan
      term:
        id: NCIT:C135627
        label: Belzutifan
  target_mechanisms:
  - target: Normoxic HIF-alpha Stabilization
    treatment_effect: INHIBITS
    description: >-
      Allosteric inhibition of HIF-2-alpha blocks the dominant effector isoform at
      the node where the disease originates, rather than downstream of it.
  evidence:
  - reference: PMID:33512384
    reference_title: Therapeutic inhibition of HIF-2α reverses polycythemia and pulmonary hypertension in murine models of human diseases.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "MK-6482 treatment decreased EPO production and reversed polycythemia in all 3 mouse models."
    explanation: >-
      Establishes reversal of the erythroid phenotype by HIF-2-alpha inhibition in
      the knock-in mouse and two related models.
  - reference: PMID:33512384
    reference_title: Therapeutic inhibition of HIF-2α reverses polycythemia and pulmonary hypertension in murine models of human diseases.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Drug treatment also decreased right ventricular pressure and mitigated pulmonary hypertension in VhlR200W, Irp1-KO, and VhlR200W;Irp1-KO mice to near normal wild-type levels and normalized the movement of the cardiac interventricular septum in VhlR200Wmice."
    explanation: >-
      Extends the preclinical benefit to the pulmonary vascular arm.
- name: Tempol (IRP1-Mediated HIF-2-alpha Repression)
  description: >-
    A mouse-only strategy that works by a different route to the same target.
    Dietary Tempol increases the iron-responsive-element binding activity of Irp1,
    which translationally represses Hif2a. In VhlR200W mice it decreased
    erythropoietin production, corrected splenomegaly, normalized hematocrit, and
    increased lifespan, and the effect was abolished when Irp1 was genetically
    ablated, which is a clean demonstration that the mechanism is the one
    proposed. No human data exist.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_mechanisms:
  - target: Normoxic HIF-alpha Stabilization
    treatment_effect: INHIBITS
    description: >-
      Tempol represses HIF-2-alpha translationally through Irp1, lowering the
      stabilized HIF-2-alpha pool. Demonstrated only in mice.
  evidence:
  - reference: PMID:29480820
    reference_title: Translational repression of HIF2α expression in mice with Chuvash polycythemia reverses polycythemia.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Here, we fed VhlR200W mice supplemented with Tempol, a small, stable nitroxide molecule and observed that Tempol decreased erythropoietin production, corrected splenomegaly, normalized hematocrit levels, and increased the lifespans of these mice."
    explanation: >-
      Documents the preclinical benefit including a survival effect.
  - reference: PMID:29480820
    reference_title: Translational repression of HIF2α expression in mice with Chuvash polycythemia reverses polycythemia.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "We attribute the reversal of erythrocytosis/polycythemia to translational repression of Hif2α expression by Tempol-mediated increases in the IRE-binding activity of Irp1, as reversal of polycythemia was abrogated in VhlR200W mice in which Irp1 was genetically ablated."
    explanation: >-
      The Irp1-knockout abrogation establishes that the benefit runs through the
      proposed mechanism.
animal_models:
- name: VhlR200W knock-in mouse
  species: Mouse
  genotype: Vhl R200W homozygous knock-in
  description: >-
    A knock-in mouse homozygous for the same R200W substitution, and the workhorse
    of the field. It recapitulates the polycythemia, the enhanced normoxic
    respiration, and the pulmonary hypertension, and it has been the system in
    which the isoform question, the therapeutic questions, and the
    pulmonary-versus-erythroid independence question were all settled.
  publication: PMID:20197624
  modeled_mechanisms:
  - target: Pulmonary Vascular Tone and Remodeling
    relationship: RECAPITULATES
    fidelity: HIGH
    description: >-
      The mouse develops pulmonary hypertension independently of the polycythemia,
      with vascular remodeling, hemorrhage, edema, and macrophage infiltration, and
      Hif2a heterozygosity suppresses it. This is what establishes the pulmonary
      arm as a parallel branch rather than a consequence of the raised hematocrit.
    limitations: >-
      Older mice additionally develop pulmonary fibrosis, which is not a
      documented feature of the human disease, so the model overshoots on that
      axis. Mouse pulmonary vascular physiology differs from human, and the
      inflammatory component was not suppressed by Hif2a heterozygosity even
      though the vascular changes were.
    evidence:
    - reference: PMID:20197624
      reference_title: The von Hippel-Lindau Chuvash mutation promotes pulmonary hypertension and fibrosis in mice.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "These mice developed pulmonary hypertension independently of polycythemia and enhanced normoxic respiration similar to Chuvash patients, further validating VhlR/R mice as a model for Chuvash disease."
      explanation: >-
        The authors' own validation statement for the model against the human
        phenotype.
  - target: Normoxic HIF-alpha Stabilization
    relationship: PERTURBS
    fidelity: HIGH
    description: >-
      Genetic reduction of Hif2a, but not Hif1a, in this background suppresses both
      the polycythemia and the pulmonary hypertension, which is the experiment that
      assigns isoform responsibility.
    limitations: >-
      Epistasis in the mouse assigns the dominant effector isoform but does not
      exclude a HIF-1-alpha contribution to other arms of the human phenotype,
      notably the metabolic one, and human patients have both isoforms elevated.
    evidence:
    - reference: PMID:20197624
      reference_title: The von Hippel-Lindau Chuvash mutation promotes pulmonary hypertension and fibrosis in mice.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "HIF-2alpha activity was increased in lungs from VhlR/R mice, and heterozygosity for Hif2a, but not Hif1a, genetically suppressed both the polycythemia and pulmonary hypertension in the VhlR/R mice."
      explanation: >-
        The genetic epistasis result establishing HIF-2-alpha as the dominant
        effector.
discussions:
- discussion_id: chuvash_absent_tumor_phenotype
  kind: OPEN_QUESTION
  prompt: >-
    Why does a homozygous germline VHL mutation not cause the tumors that define
    von Hippel-Lindau syndrome?
  attaches_to:
  - pathophysiology#Impaired pVHL Binding to Hydroxylated HIF-alpha
  rationale: >-
    This is an absence with a mechanism, and worth curating as one. Three
    explanations converge. First, dose: R200W is a hypomorph retaining substantial
    pVHL function, whereas classical VHL tumors require much deeper biallelic
    inactivation. Second, sufficiency: the matched cohort found no
    hemangioblastomas, renal carcinomas, or pheochromocytomas despite raised
    HIF-1-alpha and vascular endothelial growth factor, so HIF overexpression is
    not sufficient for tumorigenesis. Third, a preserved HIF-independent function:
    pVHL stabilizes hydroxylated TFAM to sustain mitochondrial biogenesis,
    tumorigenic VHL variants fail to bind hydroxylated TFAM, and the R200W protein
    still binds it. That last result is a clean molecular dissociation between the
    erythrocytosis arm and the oncogenic arm.
  evidence:
  - reference: PMID:14726398
    reference_title: "Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Spinocerebellar hemangioblastomas, renal carcinomas, and pheochromocytomas typical of classical VHL syndrome were not found, suggesting that overexpression of HIF-1alpha and VEGF is not sufficient for tumorigenesis."
    explanation: >-
      The sufficiency argument, stated by the authors from matched-cohort data.
  - reference: PMID:35760869
    reference_title: Impaired oxygen-sensitive regulation of mitochondrial biogenesis within the von Hippel-Lindau syndrome.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "In contrast, cells harbouring the Chuvash polycythaemia VHLR200W mutation, involved in hypoxia-sensing disorders without tumour development, are capable of binding hydroxylated TFAM."
    explanation: >-
      The preserved-function argument: R200W retains the HIF-independent TFAM
      interaction that tumorigenic variants lose.
- discussion_id: chuvash_hif2a_inhibition_outcome_endpoint
  kind: KNOWLEDGE_GAP
  prompt: >-
    Does HIF-2-alpha inhibition reduce thrombosis and mortality in VHL R200W
    homozygotes, or does it only normalize the hematocrit, which is not what kills
    people?
  attaches_to:
  - pathophysiology#Prothrombotic State
  rationale: >-
    Belzutifan reverses polycythemia and pulmonary hypertension in the mouse, and
    a human case of response exists in a compound heterozygote. But the disease's
    own literature has established that hematocrit is not the determinant of
    thrombotic risk, so a therapy validated on hematocrit is being validated on
    the wrong endpoint. The trial that matters would have to be powered on
    thrombotic events, in R200W homozygotes, with erythropoietin rather than
    hematocrit as the intermediate marker. Belzutifan also carries a known anemia
    and hypoxia toxicity profile, and HIF-2-alpha inhibition overshoots easily.
  proposed_experiments:
  - experiment_id: chuvash_hif2a_thrombosis_endpoint_trial
    name: HIF-2-alpha inhibition with a thrombotic-event endpoint
    description: >-
      A controlled trial of HIF-2-alpha inhibition in VHL R200W homozygotes
      powered on incident thrombotic events rather than hematocrit, with serum
      erythropoietin as the mechanistic intermediate and haemoglobin monitored for
      the known overshoot into anemia.
  evidence:
  - reference: PMID:37435906
    reference_title: Increased transferrin protects from thrombosis in Chuvash erythrocytosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Erythropoietin elevation, but not hematocrit or ferritin, correlated with thrombosis risk."
    explanation: >-
      Establishes why a hematocrit endpoint would not answer the question that
      matters.
- discussion_id: chuvash_iron_repletion_question
  kind: KNOWLEDGE_GAP
  prompt: >-
    Should iron be repleted in Chuvash erythrocytosis, given that iron deficiency
    raises pulmonary artery pressure but iron repletion has never been studied in a
    patient with suppressed hepcidin and HIF-driven iron avidity?
  attaches_to:
  - pathophysiology#Hepcidin Suppression and Iron Mobilization
  rationale: >-
    Low ferritin independently predicts higher tricuspid regurgitation velocity,
    and the commonest cause of low ferritin in these patients is the phlebotomy
    their doctors prescribe. The obvious corrective, iron repletion, has not been
    tested in a physiology where hepcidin is suppressed threefold and transferrin
    and transferrin receptor are transcriptionally induced. There is also a signal
    that iron status determines which HIF isoform dominates, so repletion could
    shift the phenotype in a direction that is not simply the reverse of the
    depletion.
  evidence:
  - reference: PMID:21993671
    reference_title: Pulmonary artery pressure and iron deficiency in patients with upregulation of hypoxia sensing due to homozygous VHL(R200W) mutation (Chuvash polycythemia).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Lower ferritin concentration, which is associated with phlebotomy, independently predicts higher tricuspid regurgitation velocity (www.clinicaltrials.gov identifier NCT00495638)."
    explanation: >-
      Establishes the harm of the iron-depleted state and its iatrogenic origin,
      which is what makes repletion an urgent open question.
- discussion_id: chuvash_no_controlled_trials
  kind: KNOWLEDGE_GAP
  prompt: >-
    Does any current management of Chuvash erythrocytosis change outcome?
  attaches_to:
  - treatments#Therapeutic Phlebotomy
  rationale: >-
    There are no randomized trials in this disease. Everything in the treatments
    section is cohort inference, expert opinion, mouse data, or single cases. The
    two most-used interventions, phlebotomy and aspirin, have both failed to show
    benefit in retrospective analysis, and phlebotomy is additionally associated
    with harm on two separate axes. The authors of the definitive cohort work
    called for prospective study two decades ago and it has not happened.
  evidence:
  - reference: PMID:16673284
    reference_title: Vascular complications in Chuvash polycythemia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Retrospective analyses among patients with Chuvash polycythemia have not shown benefit for therapy with phlebotomy or aspirin, but these and other modes of therapy should be studied prospectively."
    explanation: >-
      States both the absence of demonstrated benefit and the outstanding call for
      prospective evaluation.
differential_diagnoses:
- name: Polycythemia Vera
  description: >-
    The principal differential and the one whose management rules must not be
    carried over. Polycythemia vera is an acquired JAK2-mutated myeloproliferative
    neoplasm with trilineage expansion and low erythropoietin. Chuvash
    erythrocytosis is congenital, JAK2-unmutated, has high or
    inappropriately-normal erythropoietin, and has normal or low white cell and
    platelet counts. Applying the polycythemia vera hematocrit target here is the
    specific error the recent literature warns against.
  distinguishing_features:
  - JAK2 V617F or exon 12 mutation present in polycythemia vera, absent here
  - Erythropoietin low in polycythemia vera, high or inappropriately normal here
  - Leukocytosis and thrombocytosis in polycythemia vera; normal or low counts here
  - Acquired adult onset versus congenital lifelong erythrocytosis
  evidence:
  - reference: PMID:9058738
    reference_title: Congenital polycythemia in Chuvashia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "while platelet and white blood cell counts were normal"
    explanation: >-
      The normal platelet and white cell counts are the bedside discriminator from
      the trilineage expansion of polycythemia vera.
- name: Classical von Hippel-Lindau Syndrome
  description: >-
    Same gene, opposite disease. Classical VHL syndrome is autosomal dominant,
    tumor-predominant (hemangioblastoma, clear cell renal cell carcinoma,
    pheochromocytoma), and erythrocytosis is uncommon. Chuvash erythrocytosis is
    recessive, hypomorphic, and has no demonstrated excess cancer risk. Routine
    lifelong VHL tumor surveillance is not standard for R200W homozygotes.
  distinguishing_features:
  - Autosomal dominant heterozygous VHL loss versus homozygous hypomorphic R200W
  - Tumor predisposition versus no demonstrated excess cancer risk
  - Erythrocytosis uncommon versus obligate
  evidence:
  - reference: PMID:16673284
    reference_title: Vascular complications in Chuvash polycythemia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Spinocerebellar hemangioblastomas, renal carcinomas, and pheochromocytomas typical of classical VHL tumor predisposition syndrome have not been found, and no increased risk of cancer has been demonstrated."
    explanation: >-
      Establishes the absence of the classical VHL tumor spectrum in this disease.
- name: Croatian VHL H191D Homozygous Erythrocytosis
  description: >-
    The other known inherited homozygous VHL erythrocytosis, and phenotypically
    distinct rather than a variant of the same thing. H191D homozygotes have
    higher erythropoietin for age, and their erythroid progenitors are not
    hypersensitive to erythropoietin, unlike R200W. Curating them together would
    obscure exactly the asymmetry that constrains mechanistic models.
  distinguishing_features:
  - VHL c.571C>G p.His191Asp rather than c.598C>T p.Arg200Trp
  - Higher erythropoietin levels for age than R200W patients
  - Erythroid progenitors not hypersensitive to erythropoietin
  evidence:
  - reference: PMID:23403324
    reference_title: "The phenotype of polycythemia due to Croatian homozygous VHL (571C>G:H191D) mutation is different from that of Chuvash polycythemia (VHL 598C>T:R200W)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We show that erythropoietin levels in homozygous VHL H191D individuals are higher than in VHL R200W patients of similar ages, and their native erythroid progenitors, unlike Chuvash R200W, are not hypersensitive to erythropoietin."
    explanation: >-
      Documents the two phenotypic discriminators between the genotypes.
- name: EPOR-Related and High-Oxygen-Affinity Erythrocytosis
  description: >-
    The other congenital erythrocytoses, separated by two cheap tests.
    EPOR-truncation erythrocytosis is autosomal dominant with uniquely subnormal
    erythropoietin. High-oxygen-affinity hemoglobin variants and 2,3-BPG
    deficiency give a left-shifted p50, which is normal in Chuvash erythrocytosis.
  distinguishing_features:
  - Subnormal erythropoietin in EPOR-related erythrocytosis
  - Left-shifted p50 in high-affinity hemoglobinopathy and BPGM deficiency
  - Autosomal dominant transmission in EPOR and most high-affinity variants
  evidence:
  - reference: PMID:34021251
    reference_title: "JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Workup for hereditary/congenital erythrocytosis requires documentation of family history and laboratory screening for high-oxygen affinity hemoglobin variants, 2, 3 biphosphoglycerate deficiency, and germline mutations that are known to alter cellular oxygen sensing (e.g., PHD2, HIF2A, VHL) or EPO signaling (e.g., EPOR mutations); the latter is uniquely associated with subnormal EPO."
    explanation: >-
      Sets out the discriminating tests and the uniquely subnormal erythropoietin
      of EPOR-related disease.
notes: >-
  The hematocrit point is the load-bearing one. The intuitive causal chain, high
  hematocrit to viscous blood to clots, is wrong in this disease, and the
  pathograph is built to say so: the edge to the prothrombotic state runs from HIF
  target gene activation directly, in parallel with the erythroid arm rather than
  through it. Erythropoietin elevation, not hematocrit and not ferritin, is what
  correlated with thrombosis over eleven years of prospective follow-up.

  Belzutifan. There is a published human case of response to belzutifan in
  VHL-related congenital polycythemia (PMID:39113647), but two things keep it out
  of the evidence blocks. The patient was a compound heterozygote (R200W plus
  c.562C>G), not a Chuvash R200W homozygote, and the cached record for that report
  has no retrievable abstract text, so there is nothing quotable. The treatment
  entry therefore carries only the mouse evidence and says so.

  Two further sources could not be quoted for the same reason. PMID:31289208, the
  letter whose title states outright that thrombotic risk is not associated with
  elevated hematocrit, caches with no content, so that claim is carried by
  PMID:30872370 and PMID:37435906 instead, which state it in their abstracts.

  Module conformance. The pulmonary node declares conformance to
  pulmonary_vascular_remodeling. Conformance to thrombogenesis was considered and
  deliberately not declared: the evidence here is for elevated plasminogen
  activator inhibitor-1, vascular endothelial growth factor, and endothelin-1 with
  a prothrombotic transcriptional milieu, which is not the same claim as the
  module's coagulation-cascade and thrombin-driven fibrin node, and asserting it
  would overstate what the cited abstracts establish.

  Prevalence. Orphanet records worldwide prevalence as unknown and not yet
  validated. The endemic allele frequencies (0.070 Ischia, 0.057 Chuvashia) are
  recorded as a carrier-frequency measure rather than converted to a homozygote
  prevalence, because that conversion would be Hardy-Weinberg arithmetic rather
  than a published figure.

  Deep research. Curated from a claude_code deep-research report
  (research/Chuvash_Polycythemia-deep-research-claude_code.md), whose own
  reference validation reported 52/52 references verified, 15/15 quotes valid, and
  a confabulation rate of 0.0. Every snippet used here was independently
  re-verified against the cached PubMed record.
datasets:
references:
- reference: PMID:12415268
  title: Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia.
- reference: PMID:9058738
  title: Congenital polycythemia in Chuvashia.
- reference: PMID:14726398
  title: "Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors."
- reference: PMID:16673284
  title: Vascular complications in Chuvash polycythemia.
- reference: PMID:37435906
  title: Increased transferrin protects from thrombosis in Chuvash erythrocytosis.
- reference: PMID:30872370
  title: Re-evaluation of hematocrit as a determinant of thrombotic risk in erythrocytosis.
- reference: PMID:21993671
  title: Pulmonary artery pressure and iron deficiency in patients with upregulation of hypoxia sensing due to homozygous VHL(R200W) mutation (Chuvash polycythemia).
- reference: PMID:21876117
  title: Chuvash polycythemia VHLR200W mutation is associated with down-regulation of hepcidin expression.
- reference: PMID:16768548
  title: Mutation of von Hippel-Lindau tumour suppressor and human cardiopulmonary physiology.
- reference: PMID:16769575
  title: "Endothelin-1, vascular endothelial growth factor and systolic pulmonary artery pressure in patients with Chuvash polycythemia."
- reference: PMID:20197624
  title: The von Hippel-Lindau Chuvash mutation promotes pulmonary hypertension and fibrosis in mice.
- reference: PMID:33512384
  title: Therapeutic inhibition of HIF-2α reverses polycythemia and pulmonary hypertension in murine models of human diseases.
- reference: PMID:29480820
  title: Translational repression of HIF2α expression in mice with Chuvash polycythemia reverses polycythemia.
- reference: PMID:21685897
  title: Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia.
- reference: PMID:23403324
  title: "The phenotype of polycythemia due to Croatian homozygous VHL (571C>G:H191D) mutation is different from that of Chuvash polycythemia (VHL 598C>T:R200W)."
- reference: PMID:16210343
  title: "Von Hippel-Lindau-dependent polycythemia is endemic on the island of Ischia: identification of a novel cluster."
- reference: PMID:21606165
  title: The heterozygote advantage of the Chuvash polycythemia VHLR200W mutation may be protection against anemia.
- reference: PMID:35760869
  title: Impaired oxygen-sensitive regulation of mitochondrial biogenesis within the von Hippel-Lindau syndrome.
- reference: PMID:20616028
  title: Regulation of human metabolism by hypoxia-inducible factor.
- reference: PMID:20140661
  title: Increased size of solid organs in patients with Chuvash polycythemia and in mice with altered expression of HIF-1alpha and HIF-2alpha.
- reference: PMID:34021251
  title: "JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views."
- reference: PMID:37362405
  title: "A Screening Approach for Inherited Erythrocytosis due to the VHL:c.598C > T Mutation (Chuvash Polycythemia)."
- reference: PMID:29891534
  title: Identification of a new VHL exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease.

📚

References & Deep Research